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Ovarian cancer (OC) is the fourth most common cancer in women, and the most
lethal gynecologic malignancy in the United States. Adequate screening methodologies are
currently lacking and most women first present with either stage III or IV disease. To date,
there has been no substantial decrease in death rates and the majorities of patients relapse
and die from their disease despite response to first-line therapy. Several proteins, such as
CA-125, are elevated in OC, but none has proven specific and sensitive enough to serve as a
screening tool or for tumor cell recognition and lysis. It has been proposed that human
endogenous retrovirus sequences (HERVs) may play a role in the etiology of certain
cancers. In a previous study, we showed that HERV-K envelope (env) proteins are widely
expressed in human invasive breast cancer (BC) and ductal carcinoma in situ (DCIS), and
elicit both serologic and cell-mediated immune responses in BC patients. We also reported
the expression of multiple HERV genes and proteins in OC cell lines and tissues. In this
study, we strengthened our previous data by determining that HERV-K env mRNAs are
expressed in 69% of primary OC tissues (n=29), but in only 24% of benign tissues (N=17).
Immmunohistochemistry (IHC) staining revealed HERV-K positive cancer cells detected in
endometrioid adenocarcinoma and serous adenocarcinoma but not in benign cyst or normal
epithelium biopsies. Immunofluorescence staining (IFS) showed greater cell surface
expression of HERV-K in OC samples compared to adjacent uninvolved samples. Enzyme-
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linked immunosorbent assay (ELISA) data confirmed that a humoral immune response is
elicited against HERV-K in OC patients. T-cell responses against HERV-K in lymphocytes
from OC patients stimulated with autologous HERV-K pulsed dendritic cells included
induction of T-cell proliferation and IFN-γ production. HERV-K–specific cytolytic T cells
induced greater specific lysis of OC target cells compared to benign and adjacent uninvolved
target cells. Finally, upon T regulatory cell (T-reg) depletion, 64% of OC patients
displayed an increase in the specific lysis of target cells expressing HERV-K env protein.
These findings suggest that HERV-K env protein is a tumor-associated antigen capable of
activating both T-cell and B-cell responses in OC patients, and has great potential in the
development of immunotherapy regimens against OC.
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Chapter 1: Introduction
1.1 Retroviruses
Retroviruses are RNA viruses that are duplicated in a host cell via reverse
transcriptase (RT) to produce viral genomic DNA, which is then incorporated into the host’s
genome. Subsequent retroviral replication occurs concomitantly with the host cell’s DNA.
This reverse flow of genetic information from RNA to DNA and the establishment of DNA
in an integrated form in the host genome are defining aspects of retroviruses. The virion
particles, approximately 100nm in diameter, are spherical and are surrounded by an
envelope consisting of a lipid membrane bilayer. The surface is studded by projections of
an envelope glycoprotein. Beneath the membrane is a spherical layer of protein, called the
capsid protein, and an internal nucleocapsid. Based on new genera named by the
International Committee on Taxonomy of Viruses, simple retroviruses encode only the Gag,
Pro, and Env gene products. In addition to these gene products, complex retroviruses
encode an array of small regulatory proteins with a range of functions. The cleavage of
Gag, Pol and Env precursors forms the products in the mature infectious virions including
the following proteins: membrane-associated matrix protein, capsid, nucleocapsid,
protease, dUTPase, reverse transcriptase, integrase, surface protein (SU), and
transmembrane (TM) protein 1. Virus particles contain 2 copies of RNA of ~8 to 10 kb in
length (Figure 1).
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Figure 1: Schematic structure of a retroviral particle. The surface is studded by projections

of an envelope glycoprotein consisting of the SU and TM proteins. The matrix protein and
core shell derived from gag are depicted in the center of the virus. The 2 RNA molecules,
polymerase, RNAse, and integrase are shown within the core shell.
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Typically, the targets of retroviruses are somatic cells, however, when the target is a
gamete, the provirus becomes a permanent fixture within the offspring’s genome. Literally
meaning “born within”, these endogenous retroviruses (ERVs) are then inherited across
generations. Some of these elements first entered the primate genome more than 40 million
years ago. However, new proviral copies have been generated more recently that are human
specific 2, 3. Human endogenous retroviruses (HERVs) are believed to have entered the
human genome around 30 million years ago via infection of the germline, and since then
have persisted as stably integrated, vertically transmitted proviruses 4, 5. When we examine
the collective genome of Homo sapiens we find that humans share most of their ERVs with
chimpanzees, great apes, gibbons, and old world monkeys 6, 7. HERVs comprise up to 8%
of the human genome and are widely dispersed 8. HERVs lack mutagenic activity and in
fact nearly 90% of HERV elements exist as recombined solitary long terminal repeats
(LTRs) 8, 9 and the remainder have accumulated inactivating mutations during evolution 10.
Specifically, the majority of HERVs are incomplete and faulty in terms of replication due to
multiple termination sequences 11-15. In most cases HERVs are transcriptionally silenced by
epigenetic mechanisms including methylation, histone modifications, and small RNAs.
However, our knowledge of how these modifications demarcate and silence HERVs in the
human genome is limited.
HERVs belong to the class of retroelements, which can be subdivided into elements
with regulatory LTRs (8.3% of our DNA; 0.3 x 106 copies) and elements without LTRs
(33.9%; 2.4 x 106 copies) 16. Short and long interspersed nuclear elements (SINEs and
LINEs), members of the non-LTR group, are present in very high copy numbers. LINEs are
abundant retrotransposons that comprise approximately 20% of mammalian genomes.
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LINEs encode a RT that can be utilized for retrotranspositions of SINEs and LINEs or for
the formation of pseudogenes 16. The LTR containing retroelements can further be divided
into 6 superfamilies 17, based solely on sequence relationship: class I (gamma retroviruses)
representing most families and the largest genomic fraction 9, 18, class II (beta retroviruses)
which contain the HERV-K elements and older families 19, and class III (spuma
retroviruses) 9 which contain the oldest recognizable HERV elements 8. The other
superfamilies MER4, MST and MLT represent ancient retrotransposons with no known
functions in humans 16.

1.2 HERV-K(HML2) (human MMTV-like 2) Family
HERVs are classified into families according to the single-letter amino acid code
corresponding to the tRNA primer used for reverse transcription of the HERV genome 20.
Thus, HERV-K’s tRNA primer begins with lysine, HERV-W’s begins with tryptophan and
so on. The type K family (HERV-K) proviruses are present at approximately 30-50 copies
per haploid human genome, but many are polymorphic in humans. HERV-K is located on
chromosome 19 and possesses large open reading frames in the genes putatively encoding
Gag, Pol, Env and a protease, flanked by two non-coding LTRs 21 (Figure 2). Therefore,
HERV-Ks contain all structural features necessary for viral replication 21. The gag gene
encodes matrix, capsid (core shell proteins) and nucleocapsid proteins necessary for viral
RNA encapsidation and particle formation. The pol gene encodes the viral enzyme
machinery needed for conversion of the viral RNA to the proviral DNA form, including RT
and integrase. The env gene encodes for two different proteins important for virus
infectivity: an outer surface membrane (SU) protein and a transmembrane (TM) protein.
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The LTRs contain elements involved in transcription initiation and termination 22. HERV-K
possesses 2 accessory proteins termed Rec and Np9. Rec, a protein functionally related to
HTLV Rex and HIV Rev, is responsible for the nuclear export of unspliced or single-spliced
viral mRNA into the cytoplasm. Np9 is a nuclear protein.
Several studies have led to the identification of 18 coding env genes, with the most
important contributor being the HERV-K(HML2) family23-25 which contains six coding env
genes. The entry dates of all six copies with a coding env are less than five million years
ago.26, 27
In 1986, Ono M, Yasunaga T, Miyata T, and Ushikubo H, determined the complete
nucleotide sequence of the human endogenous retrovirus genome HERV-K10, a member of
the human endogenous retrovirus HERV-K family. The sequence was shown to be a fulllength 9.2-kb provirus with LTRs at each end 21. HERV-K22, another member, contained
an additional 292-bp sequence between the pol and env genes. Subsequently, the genome
missing the 292-bp sequence was designated “type 1” and the genome containing the 292-bp
sequence “type 2” 28. The 292 bp deletion found in HERV-K type I leads to the fusion of
the pol and the env gene and the absence of the rec gene. HERV-K type II, the HERV-K
prototype, has open reading frames (ORFs) for the structural proteins Gag and Env, RT 29,
and the regulatory protein Rec 30. These two types contain ORFs encoding genes required
for retroviral replication (Figure 2).
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Figure 2: Schematic representation of full-length HERV-K(HML-2) type 1 and 2
proviruses and their respective mRNA transcripts. There are three genetic domains, flanked
by the regulatory LTRs. The gag domain encodes for matrix and core shell (capsid)
proteins, the pol encodes for reverse transcriptase, protease, integrase and ribonuclease, and
the env encodes for the surface and transmembrane proteins. Splice donor (SD) and splice
acceptor (SA) sites are shown. There are two types of HERV-K (HML-2) proviruses in the
human genome differing by the presence (type 2; black rectangle) or absence (type 1;D292bp) of a 292-bp sequence at the pol-env boundary 28. HERV-K(HML-2.HOM) is an
example of a type 2 provirus, HERV-K101 an example of a type 1 provirus. In type 2
proviruses, the 292-bp sequence harbors a splice donor site (SD2b) involved in the
generation of doubly spliced transcripts coding for the two exons (light grey and dark grey
boxes) of the accessory ~15kDa protein Rec by some type 2 proviruses 30, 31. In type 1
proviruses, an alternative splice donor (SD2a) located upstream of the 292-bp stretch is used
to generate mRNAs coding for Np9 32. Np9 is an ~9 kDa, 74-amino acid protein that shares
its 14 N-terminal amino acids (exon 1, light grey box) with Rec and Env, whereas the 60 Cterminal amino acids (exon 2, dark grey box) are derived from the third (non-Rec, non-Env)
ORF. Numbers on top of rec and np9 transcripts indicate the reading frames. Adopted from
reference 33 with permission from Springer.
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1.3 Normal physiological effects of HERV
A very small proportion of HERVs can potentially encode proteins, however this
proportion has led to a multitudinous amount of data showing that these and other defective
copies are actively transcribed. This insinuates that many LTRs possess retained
transcriptional regulatory functions that confer a beneficial function. Indeed, the fact that
HERVs constitute approximately 8.3% of the human genome efficaciously asserts the theory
that HERVs have provided some evolutionary advantages at the population level, and in fact
several advantages have been proposed. First, HERVs constitute sequences that are
substrates for genomic rearrangements and therefore could contribute to modeling and the
plasticity of the genome 33. Also of importance, retroviral LTRs naturally possess enhancer,
promoter, and polyadenylation activities 34. Therefore HERV LTRs can provide tissuespecific enhancers, alternative promoters, or alternative polyadenylation signals for nearby
genes 18. Indeed, LTRs function as promoters of retroviral genes and sometimes function as
promoters of nearby cellular genes 35-38. In fact, at least 50% of the human-specific HERVK LTRs act in vivo as active promoters for non-repetitive DNA transcription 39. For
example, HERV LTRs account for over 30% of all p53 binding sites genome-wide,
therefore contributing to the anti-oncogenic function of p53 40. Also, Mager DL, Hunter
DG, Schertzer M, and Freeman JD, identified two human genes, HHLA2 and HHLA3, for
which HERV-H LTR served as the primary polyadenylation signal. Although the functions
of the particular genes were unknown, this data supports the fact that retroviral LTRs
assume gene regulatory functions 41.
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Another advantage is the possibility that the presence of ERVs may protect
organisms from infections by related exogenous retroviruses via receptor interference 42, 43.
For example, HERV-W envelope glycoproteins have been shown to confer cellular
resistance to superinfection by exogenous retroviruses 44. Finally, to support the idea of
physiological in vivo functions of HERV-encoded proteins, Mi S, Lee X, Li X, Veldman
GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, Keith JC Jr, and
McCoy JM, showed in 2000, that the env protein of HERV-W, termed Syncytin-1, mediates
the formation of syncytiotrophoblasts from cytotrophoblasts which is a key step in normal
placental morphogenesis 45-47. Another example of beneficial functions of HERV-encoded
proteins involves HERV-E, which is activated in a proportion of renal cancer cells. In a
recent clinical study, HERV-E provided target antigens recognizable by cytotoxic T cells
from donors after allogenic hematopoetic stem cell transplantation, leading to complete or
partial tumor regression in patients 48.

1.4 HERV and Human Disease
One hundred years after Francis Peyton Rous demonstrated that cancer could be
caused by a virus, science has elucidated seven human viruses that have been found to cause
10-15% of human cancers worldwide. The International Agency for Research on Cancer
estimates that one in five cancer cases worldwide are caused by infection, with most caused
by viruses 49, 50. These cancers are serious public health problems but most importantly
these cancers have readily identifiable targets for diagnosis, prevention and therapy 51.
Vaccination programs against hepatitis B virus (HBV) and human papilloma-virus (HPV),
both human tumor viruses, have already made huge impacts on worldwide cancer rates 52-54.
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However, modern science has since shown that in human cancer, virus infection alone is not
sufficient for tumorigenesis. Cancer is a complex multistep process and it is the culmination
of various molecular events that generate the final transformed cellular phenotype. Viruses
can be divided into two groups based on the roles they play in tumorigenesis. Direct
carcinogens express viral oncogenes in each cancer cell that directly contribute to cancer cell
transformation and indirect carcinogens cause cancer through chronic infections and
inflammation, ultimately leading to carcinogenic mutations 55. With respect to HERV-K,
the exact role it plays in cancer is unknown and future studies are needed to determine its
carcinogenic effects.
For many decades, HERV expression at the protein and RNA levels was found to be
associated with cancer and autoimmune diseases 56-59. Indeed, the expression, promoter
activity, and epigenetic regulation of HERV-Ks are extremely different between malignant
and normal cells. Numerous studies have documented an increased expression of HERVs in
terms of both transcriptional and protein levels in tumors, with the majority of research on
the HERV-K family (Table 1).
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Table 1: Expression of HERVs in human cancer: Expression of various HERV types is
shown in various tumor types. The detection of viral genes at the transcriptional (RNA) or
translational levels (P) is shown. Adapted from reference 10 with permission from Elsevier.
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At the time the complete nucleotide sequence of HERV-K10 and HERV-K22was
determined 21, the types, structures, and functions of human endogenous retroviruses and
their relationships to human cancer were not known. However, Ono and his colleagues
advocated the possibility that a particular antigen expressed in human BC tissue and T47D
cells was the env gene product of a potentially active HERV-K provirus. The following
year, Ono M, Kawakami M, and Ushikubo H determined that stimulation of HERV-K
genome expression was observed in the human BC cell line T47D after estradiol treatment
60

. Correspondingly, Lower R, Lower J, Tondera-Koch C, and Kurth R demonstrated that

upon steroid hormone treatment, human teratocarcinoma cells showed an increase in
expression of the HERV-K genome and production of retroviral-like particles 61. Similarly
to the teratocarcinoma cells and supporting the data from the previous studies, T47D cells
also showed an increase in the expression of the HERV-K genome and the production of
retroviral-like particles upon hormone stimulation 62-64. In addition, Etkind PR, Lumb K, Du
J, and Racevskis J determined that T47D contains the type 1 HERV-K genome which is
spliced to subgenomic transcripts 65.
Willer and his colleagues were the first to characterize the HERV-K env
transcription pattern in several malignant tissues and in peripheral blood mononuclear cells
(PBMCs) via RT-PCR 66. HERV-K env transcripts were found in all of the following
tissues: BC, Hodgkin’s disease, thyroid adenoma (TA), colon cancer, chronic myelogenous
leukemia (CML), high and low grade non-Hodgkin’s lymphomas, and myelodysplastic
syndrome. HERV-K env transcripts were also found in PBMCs from patients with gastric
cancer, and BC.

11

In 2001, Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF,
Shaw DR, and Strong TV investigated the expression of HERV sequences in BC and
determined that indeed HERV-K transcripts are specifically and frequently expressed. The
group further substantiated their results by determining that some of these transcripts
contained ORFs that produced env protein 67. To build on this knowledge, the same group
investigated the expression of type 2 HERV-K env mRNAs and the splicing patterns of both
types of HERV-K in human BC tissues. They discovered that there was an increase in
HERV-K env and spliced env expression in human BC tissues. Specifically, type 2 HERVK env transcripts were detected in human BCs. Of great importance, expression was
significantly higher in most BC tissues than in normal breast tissues 68.
In an exceptional study by Dewannieux M, Blaise S, and Heidmann T, it was
demonstrated that a member of the HERV-K family, termed K108, encoded a functional env
protein 69. They discovered that the env protein was exported to the cell surface, cleaved
into SU and TM subunits, and generated infectious pseudotyped particles. Combined with
the data that HERV-K-related particles had been detected in culture supernatants from
teratocarcinoma and melanoma cell lines, these findings gave credence to the idea that
infectious retroviruses could be produced if they incorporated the HERV-K108 env protein
3, 24, 28, 70

.

Another study by Dewannieux and his colleagues helped to unify the preceding
results by showing it was possible to derive the sequence of HERV-K and construct a
consensus HERV-K provirus, which they termed Phoenix 71. The element produced viral
particles complete with structural and functional properties of a retrovirus and had the ability

12

to infect human cells. Upon infection, Phoenix integrated with the exact signature of the
presently found endogenous HERV-K progeny. Significantly, they showed that in vitro
recombination among present-day human HERV-K loci can generate functional elements,
indicating the possibility that human cells can produce infectious retroviruses 71. Similarly,
in an exciting 2008 paper, Boller and his colleagues proved that the HERV-K provirus is
capable of producing intact retroviral particles when cloned into a baculovirus expression
vector, exposing a real-life active human endogenous retrovirus of today 72.
Studies reporting the presence of retrovirus-like particles in human melanomas date
back to the 1970s 73, 74, however it wasn’t until 2003, that Muster T, Waltenberger A, and
Grassauer A made a novel discovery by showing that retrovirus-like particles, which exhibit
RT activity and have homologous sequences to HERV-K, are produced by human
melanoma cells. This group also showed expression of the pol gene and Gag, Env, and Rec
proteins in human melanomas. Most importantly, these expressions were not seen in
melanocytes or normal lymph nodes 75. To supplement this data, Buscher K, Trefzer U,
Hofmann M, Sterry W, Kurth R, and Denner J, showed expression of viral proteins in
melanomas and the presence of HERV-K-specific antibodies in patients with melanomas 76.
Hahn S, Ugurel S, Hanschmann HM, Strobel H, Tondera C, Schadendorf D, Lower J, and
Lower R expounded on the discovery that expression of HERV-K proteins induce humoral
immune responses in melanoma, and showed that serological response to HERV-K
correlated with survival probability in melanoma patients. The hope at that point was the
possibility of using anti-HERV-K reactivity as a way to monitor patients suffering from
melanoma 77.
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A key paper in the discovery of potential mechanisms of HERV-K came from
Serafino A, Balestrieri E, Piermarchi P, Matteucci C, Moroni G, Oricchio E, Rasi G,
Mastino A, Spadafora C, Garaci E, and Vellabona PS

78

. He and his colleagues

demonstrated that human melanoma cell lines undergo a variety of morphological and
molecular alterations typical of malignant cells in response to a massive HERV-K
expression and subsequent production of HERV-K-related viral-like particles. This strongly
indicated that activation of HERV-K expression is a key element in morphological and
functional cell changes during melanoma progression 78.
Several groups have found cytotoxic T-lymphocyte (CTL) responses against HERVK antigens in melanoma patients and seminoma patients 79, 80. The first evidence that
HERV-encoded peptides expressed in human tumor cells could also be targets for antitumor
cytotoxic CD8+ T cell responses, came from a study that identified a HERV-K (HML-6)encoded HLA-A2-restricted peptide (HERV-K-Mel) which was recognized in autologous
melanoma cells by CTLs from two patients with melanomas 80. This suggested that HERVK proteins can function as tumor antigens that are targeted by CTLs and could potentially be
used for vaccination.
In terms of research on expression of HERV families in other cancers, a paper by
Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV,
Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X,
Lerman MI, and Childs RW showed that HERV-E is expressed in renal cell carcinoma
(RCC) and is highly immunogenic 81. HERV-E expression has also been implicated in
prostate cancer 82 and a recent study by Ishida T, Obata Y, Ohara N, Matsushita H, Sato S,
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Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T,
Morishima T, Old LJ, and Nakayama E identified the HERV-K gag protein in serum from
prostate cancer patients 83. HERV-H expression has been shown in gastrointestinal cancer
84

. Transcripts containing the HERV-A LTR sequence were even found in a lung cancer cell

line with no transcripts detectable in normal lung tissue 85. HERV-K-MEL was found to be
expressed with a high prevalence in pancreatic cancer patients 86. In terms of diseases other
than cancer, it has been shown that HERV-K viral load can be detected in plasma samples
from rheumatoid arthritis patients. Specifically, viral load is higher in plasma samples from
those with active disease 87. HERVs have also been shown to be expressed in brain from
patients with multiple sclerosis 88, 89. In an innovative study, Contreras-Galindo R, Kaplan
MH, Markovitz DM, Lorenzo E, and Yamamura Y illustrated that type 1 and type 2 HERVK viral RNA genomes were found to coexist in the same plasma of HIV-1 patients 90. The
same group later showed that HIV-1 viral particles upregulated HERV-K RNA in a dosedependent manner 91. Extending these results, it was also observed that HERV (-H, -K, and
-L family)-specific T cell responses in HIV-1-infected individuals were identified and
inversely correlated with HIV-1 plasma viral load and positively correlated with CD4+ T
cells counts. These results generated the idea that HERV-specific T cells may potentially
participate in controlling HIV-1 replication and that therapeutics targeting HIV-1-infected
cells with HERV specific cytotoxic T cells could be beneficial 92, 93.

1.5 HERV-K in BC in our laboratory
For many years our laboratory has focused on BC and HERV-K env protein
expression. In 2008, we demonstrated that HERV-K env proteins are strongly expressed in
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human invasive BC and DCIS, and are correlated with lymph node metastasis in comparison
with adjacent benign tissues. We further showed that HERV-K env protein elicits both
serologic and cell-mediated immune responses. Specifically, CD8+ T-cell proliferation
specific for HERV-K was detected in PBMCs in a high proportion of BC patients after in
vitro stimulation with the HERV-K protein. CD8+ cytotoxic T-cells also specifically killed
HERV-K expressing established target cells. More importantly, little or no responses were
detected in lymphocytes from normal donors 94.
To reinforce these conclusions, we obtained samples from new patient cohorts from
the U.S. and China and illustrated that the HERV-K env gene is expressed in the majority of
BC samples from both cohorts but not in adjacent noncancerous tissue or normal breast
tissue. HERV-K env protein expression was significantly associated with disease stage, a
positive node status, and poor disease outcome, suggesting expression may enhance
metastatic spread in women diagnosed with BC. However, HERV-K env expression was
not associated with age, ER or PR protein expression, or histological grade. We therefore
concluded that activation of HERVs appear to be a common event in BC regardless of
geographic location.95
In 2012, we combined our HERV-K knowledge with cancer immunotherapeutics and
were the first to show that monoclonal and single-chain antibodies against the HERV-K env
were capable of blocking growth and proliferation, and inducing apoptosis of human BC
cells in vitro. We also demonstrated that treatment with an anti-HERV-K monoclonal
antibody (mAb) significantly inhibited tumor growth in mice bearing BC xenograft tumors
96

.
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1.6 Proposed functions of HERVs in Human Disease
HERVs have been implicated in the pathogenesis of diseases, in particular cancer
and autoimmunity 97, however the specific role they play remains an enigma. HERVs have
resided in their host genomes for millions of years and still show similarities with exogenous
infectious retroviruses with respect to internal genome organization and the presence of
LTRs. The idea that endogenous retroviral elements play key biological roles is bolstered
by their significant distribution in mammalian genomes. Therefore, much consideration had
been given to the specific functions of HERVs in these biological roles, producing several
diverse mechanisms (Figure 3). Firstly, HERVs could be acting as intra or interchromosomal recombination sites causing genomic plasticity and chromosomal aberrations.
Non-allelic homologous recombination (NAHR) between members of the same endogenous
viral element family that are located on the same or different chromosomes may lead to
genomic rearrangements such as deletion, duplication, inversion or translocation events 98.
A recent study of HERV-K shows that 6 (17%) of the 35 full-length copies examined have
undergone some form of NAHR following insertion 99.

Indeed somatic rearrangements

might be relevant for tumorigenesis, for example, a recurrent translocation event that creates
an oncogenic HERV-K-ETS translocation variant 1 (ETV1) fusion gene has been implicated
in prostate cancer 100. Secondly, proviral insertions may produce somatic or germ line
mutations resulting in a loss of cellular gene function. Even though no replicationcompetent HERV has been identified in the human genome to date, the idea of insertional
mutagenesis continues to be of considerable interest. Thirdly, solitary or proviral LTRs
could possibly modulate adjacent cellular gene expression. Finally, expression of HERV
specific proteins may have a pathological influence 22 (Figure 3).
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Two processes implicate the mechanism of tumor immune escape mediated by
immunosuppressive endogenous retroviral Env proteins. One process is in the induction of
immune tolerance at the materno-fetal barrier via a physiological expression in the placenta
101

. The other process is the suppression of an antitumoral immune response through

aberrant expression in cancers. Also, data has shown that HERV-K accessory proteins, both
Rec and Np9, have demonstrated oncogenic properties. The first strong evidence that Rec
expression causes the development of germ cell tumors in vivo, was by Boese A, Sauter M,
Galli U, Best B, Herbst H, Mayer J, Kremmer E, Roemer K, Mueller-Lantzsch N in 2000
102

. To understand the molecular mechanisms underlying the oncogenic effect seen in Rec

expression, studies were executed to discover proteins that interacted with Rec. One of these
proteins was the promyelocytic leukemia zinc finger (PLZF) protein 102, which is a tumor
suppressor, transcriptional repressor of the c-myc proto-oncogene, and spermatogonial stem
cell regulator. Cells stably transfected with PLZF and Rec showed increased cell
proliferation and a reduced apoptosis rate compared to cells stably transfected with PLZF
alone 103. After Np9 was identified 103, np9 transcripts were detected among malignant
cells but not in normal cells 32. Np9 was later found to directly interfere with an ubiquitin
ligase that regulates the transcription factor Notch via degradation of the Notch-antagonist
Numb104. The Numb/Notch pathway is an essential part of the proproliferative Ras
signaling, and more importantly has been suggested to be involved in germ cell tumors by
causing genetic instability 105. The regulation and effector pathways of Rec and Np9 need to
be further explored in order to determine the complete contribution of these proteins in
human disease.
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Figure 3: Possible mechanisms by which HERVs could be involved in tumorigenesis. A
simplified scheme of tumorigenesis and potential fates of malignant cells is depicted to
indicate steps in tumorigenesis in which HERVs may play a role. The process by which a
normal cell (green nucleus) turns into a cancer cell (red nucleus) is referred to as malignant
transformation. Possible mechanisms by which HERVs contribute to malignant
transformation are listed. Malignant cells are normally controlled by the immune system
(tumor immunosurveillance). Expression of HERV antigens (HERV-Ags, green squares) on
tumor cells may elicit an antitumor immune response involving, among others, antibodies
(Ab) and CD8+ cytotoxic T cells (CTL). Ideally, antitumor immune responses result in the
elimination of cancer cells. Expression of immunosuppressive endogenous retroviral
envelope (Env, yellow triangle) proteins on tumor cells may lead to a CD4+CD25+
regulatory T cell (T-reg)-mediated suppression of antitumor CTL, leading to escape of
tumor cells from immunosurveillance (tumor escape) and consecutive invasive cancer
growth. The level of evidence of the outlined mechanisms for human cancers is indicated. *
Some evidence for potential relevance in human cancer (germ cell tumors). ** Evidence in
animal models, so far no evidence in humans. *** Hypothetical mechanism. **** Some
evidence for anti-HERV immune responses in certain human cancers; very limited data
concerning their functional relevance. Adapted from reference 33 with permission from
Springer.
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1.7 Ovarian Cancer
Ovarian cancer (OC) is the most common cause of death in gynecologic
malignancies and its prognosis has only modestly improved over the last few decades 106.
Epithelial OC, the main type of this disease, accounts for more than 90% of all malignant
ovarian tumors. Despite improvements in systemic therapy, advanced OC remains highly
lethal with more than 90% of patients developing tumor recurrence, resulting in five-year
survival rates of only 30% 107. The incidence and mortality rate of OC has remained
unchanged over the past decade and there is an obvious need for more sensitive markers to
detect OC at an early stage and to monitor disease progress. Currently there is no test with
sufficient predictive value for use in screening and detection of pre-malignant or localized
OC 108, and 70% of patients with OC present with advanced disseminated disease at the time
of initial diagnosis 109. Therefore, the identification of novel diagnostic serum biomarkers
specific to and widely expressed by early-stage OCs is urgently needed for the future
development of diagnostic tests for early detection and for development of new
immunotherapy regimens 108.
There are six tumor subclasses distinguishing patients with epithelial OC 110. The
most common form is termed serous carcinomas and represents 40% of all cases. The
remaining epithelial ovarian cancer subclasses are endometrioid, mucinous, clear cell,
transitional, and undifferentiated. Approximately 90% of epithelial ovarian cancers are
sporadic, and the remaining 10% are associated with inherited mutations in the BRACA1 or
BRACA2 functions 111, 112. Due to their anatomical location, a high percentage of ovarian
tumors disseminate throughout the peritoneal cavity and implant on various organs, thereby
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forming ascites. The following stages represent degrees of tumor dissemination: stage I-II
disease is confined to one or both ovaries, stage III disease shows peritoneal spread, and
stage IV disease shows distant metastases 113. Stage III/IV serous ovarian cancer is the most
lethal and unfortunately the most common.
In early stages, small OCs are typically difficult to detect and therefore OC is often
discovered in the late stages when it has spread beyond the ovaries. Current treatment
consists of surgical removal of the tumor, hysterectomy, salpingo-oophorectomy, and
omentectomy, followed by systemic chemotherapy. Specifically, the treatment involves
aggressive tumor cytoreductive surgery followed by platinum- and taxane-based
chemotherapy, with a response rate to first-line chemotherapy in approximately 65-80% of
patients 114. Unfortunately, most ovarian carcinomas relapse. First-line chemotherapy with
cisplatin and platinum is able to achieve complete remission in 65-80% of late stage OC
patients but these treatments are ineffective in OC relapse, and drug resistance contributes to
the comparatively low five-year survival rate.
The central premise in OC immunotherapy is that tumor-associated antigen
expression can be recognized by CTLs leading to tumor destruction 115, 116. Examples of
ovarian tumor antigens recognized by CTL include HER2, CA125, and MUC-1 117-122.
These antigens have been incorporated into cancer vaccines currently in clinical trials 123-126,
however clinical efficacy of these vaccines has exhibited only modest results. CA-125 is the
only marker approved for monitoring OC progression and treatment response, but it has a
very low sensitivity for early stage OC and accounts for a high rate of false positive values
127

.
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Several other OC antigens have been identified, however, but which antigens are
tumor rejection antigens is unknown (EGF receptor-derived peptide p971-980, FRα, IGFBP2, MUC16, p53, EpCAM, and some members of the CTA family). Ioannides and his
colleagues discovered CD8+ T cells, isolated from ovarian malignant ascites, capable of
recognizing the human EGF receptor (EGFR)2 (HER-2/neu)-derived peptide, p971-980 128.
HER-2/neu is an attractive immunologic target because of its low-level expression in
peripheral tissues. However, the percentage of ovarian tumors with HER-2/neu expression
has ranged from 5 to 66% 129-132, and data concerning the prognostic relevance of its gene
amplification or protein overexpression in OC has been contradictory. In another study,
People and his colleagues found that tumor-associated lymphocytes isolated from the
malignant ascites of OC patients recognized naturally processed and presented peptides
derived from folate receptor (FRα) 133, 134. It was also determined that FRα expression in
nonmucinous ovarian tumors increased approximately 90-fold compared with normal
epithelial cells 135. Expression of FRα is limited to a few specific tissues such as the apical
surface of kidney tubule epithelium 136. Thus, FRα is a promising therapeutic target not only
due to its tumor specificity and high-level expression, but also because it is naturally
immunogenic. However, there have been no follow-up reports confirming that FRα is an
effective tumor-associated antigen. Mutation in the p53 gene is one of the most common,
single genetic alterations in sporadic human epithelial ovarian carcinoma 137. As a result of
mutation, p53 is overexpressed in nearly 50% of OCs. However, in a recent
immunotherapeutic study, small peptides derived from TP53 delivered in an emulsionadjuvant resulted in a weak T cell response and no tumor regression in advanced OC
patients 138.
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T cells in the tumor microenvironment are key players in patient outcomes. T cell
infiltration into ovarian tumors is associated with improved survival and in tumors with high
numbers of tumor-infiltrating T lymphocyte cells (TILs), the expression of monokines
induced by IFN-γ, macrophage-derived chemokines and secondary lymphoid-tissue
chemokines, is significantly increased as compared with tumors lacking T cells 139. Thus,
the immune infiltrate has an active role in the clinical course of OC 139. It has also been
determined that there is improved survival in OC patients who have higher numbers of
intraepithelial CD8+ T cells compared with patients without intraepithelial CD8+ T cells 140.
A recent study shows a strong positive correlation between levels of CD8+ T cells and
granzyme B within ovarian tumors, indicating that the majority of CD8+ T cells are
cytotoxic 141. Concerning CD4+ helper T-cell infiltration, Kryczek and colleagues found
high levels of IL-17 associated with improved outcome suggesting that a subset of CD4+ Th
cells, Th17 cells, have a role in eradicating ovarian tumors 142. In another example,
Tomosova and his colleagues have shown that patients exhibiting higher CD3+ TIL cell
numbers had an improved overall survival than those patients with lower CD3+ cell numbers
143

. These conclusions provide possible insight needed for further immune therapies

designed to influence recruitment of helpful T cell subsets.

1.8 Immune suppression and microenvironment in ovarian cancer
A major reason for the current lack of effective immune-based treatments is that
ovarian tumors establish a complex multilayered immune suppression network which
suppresses any antitumor efforts 144. There are several mechanisms by which tumors can
arrest the immune response. First, tumors can increase the numbers of T regulatory cells (T-
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regs) in the peripheral blood of OC patients 145. Secondly, tumors can recruit or induce Treg tumor infiltration. Indeed, a study by Curiel and his colleagues demonstrated that the
accumulation of intratumoral T-regs was associated with a high mortality rate 146.
As mentioned previously, it is believed that the presence or absence of specific
populations of T cells within epithelial OC tumors is associated with important differences
in prognosis. Importantly, the detection of antitumor immune response in the form of
intraepithelial tumor infiltrating lymphocytes (TILs) predicts significantly longer survival in
OC 139. Alternatively, the presence of T-regs in ovarian tumors has been associated with
reduced overall survival 146, 147. Indeed, Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P,
Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S,
Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, and
Zou W found evidence that CD4+CD25+FOXP3+ regulatory T cells in patients with ovarian
carcinoma suppress tumor-specific T-cell immunity and contribute to growth of human
tumors in vivo 146. Also, the presence of T-regs was found in OC ascites but not in normal
ascites 148. This insinuates that T-reg depletion can possibly become a promising strategy
for boosting TAA-specific immunity149.
Vaccines have been the main approach to OC immunotherapy 108, 146, 150, 151, however
much work is needed to improved their performance. Depletion of T-regs is a critical
maneuver to enhance vaccine therapy. To test this, a pilot study at the University of
Pennsylvania is currently administering partially mature dendritic cells (DCs) pulsed with
autologous tumor cell lysate to subjects with recurrent OC in combination with immune
modulation with oral metronomic cyclophosphamide (to deplete T-regs) and bevacizumab
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(to disrupt the blood tumor endothelial barrier) 152; partial objective responses have been
observed.
In addition to infiltration by T-regs, expression of the negative regulatory co-receptor
B7-H1 by tumor cells and infiltrating myeloid DCs, expression of B7-H4 by tumorassociated macrophages, and expression of indoleamine 2,3-dioxygenase (IDO) all correlate
with increased morbidity and mortality in OC. Strategies for depletion of myeloid
suppressor cells, blockade of B7-H1 signaling, or inhibition of IDO activity are all currently
under investigation as free-standing treatments or adjuvants for active immunotherapy for
OC 153. Overcoming suppressive mechanisms found within the tumor microenvironment in
order to enhance efficacy is a major challenge for current approaches to cancer vaccination.
Recent studies have determined that the immune system plays a critical role in
controlling growth and spread of ovarian tumors and therefore it is critical for future
immunotherapies to overcome these immune inhibitory mechanisms. Various studies have
shown that OC escapes immune surveillance with high efficiency via creating a tolerogenic
microenvironment. OC-infiltrating plasmacytoid DC and macrophages produce the
chemokine CCL22 which acts via CCL4 expressed by Th2 cells154, memory T cells 155 and
regulatory T cells 156. High levels of CCL22 have been detected in OC ascites and OC but
not in normal ovaries 146. This group specifically found that CCL22 expression in the tumor
microenvironment triggers T-reg migration into the tumor lesion. They also determined that
CD4+CD25+FoxP3+ T-regs suppress tumor-specific T-cell immune responses in OC
patients, thus promoting tumor growth in vivo, and that tumor T-reg infiltration is correlated
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with reduced survival 146. This indicates that OC tumor progression exploits different types
of mechanisms to hamper the immune response and evade immune surveillance.
Limited success of cancer vaccines are also due to other negative influences in the
tumor microenvironment. One particular example pertains to the lack of T-cell
costimulatory molecules in most solid tumors. This results in activated T cells becoming
anergized and loosing lytic capacity. It has also been shown in preclinical models of chronic
viral infection that T cells chronically exposed to viral antigen can become exhausted 157, 158.
Interstitial pressure within a large tumor mass is another negative influence as it diminishes
diffusion of macromolecules such as antibodies and T cells 159, 160. Also, T-reg, tumor cells,
and other cells in the tumor microenvironment have the potential to release soluble
immunosuppressive factors including TGF-β, IL-10, indoleaimine-pyrrole 2,3 dioxygenase
(IDO) and VEGF 161-163. Finally, the phenotype of tumors also has the potential to change as
seen with the tendency for IL-8 to drive carcinoma cells to the EMT phenotype 164.
Many tumors display antigenic heterogeneity at both the level of antigen expression
and at the level of the antigen-peptide MHC complex 165. Defects in MHC-peptide
complexing machinery has also been detected in tumor cells 166-170. An example of this was
seen when cloned carcinoma cells reverted to express a more heterogenous antigenic
population upon passage. This phenomenon has also been witnessed in clinical trials in
which vaccinated patients develop higher levels of T cell responses to tumor-associated
antigens compared to the antigen in the vaccine 171-173.
As stated above, recent studies have identified a survival advantage associated
specifically with the presence of intraepithelial TILs, located in specific tumor islets 174.
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The intraepithelial TILs in OC specimens are a robust biomarker for overall survival of
women with this disease. If validated, TIL scores could be used not only to select women for
clinical trials of cancer vaccines or adoptive T cell therapies, but could also be used to select
combinations of chemotherapeutic drugs that interact positively with antitumor immune
mechanisms174.

1.9 Involvement of HERV-K in Ovarian Cancer
In a keystone 2006 paper from our laboratory, we turned our focus to another
perilous female cancer and produced cogent results demonstrating expression of multiple
HERV-K SU env proteins in OC. We also showed that in contrast to most cancers which
express 1 or 2 HERVs, at least three HERV env genes were expressed in OC, including
HERV-K Types 1 and 2, ERV3, and HERV-E 175. Specifically, Type 1 (1,105 bp) and Type
II (1,195 bp) HERV-K surface domains were detected at a higher frequency in established
OC cell lines compared to normal epithelial cells or immortalized normal ovarian cell lines.
Also in this study, expression of HERV-K env mRNA was greater in ovarian epithelial
tumors compared to normal ovarian tissues (n=254). We also determined both cytoplasmic
and cell surface expression of HERV-K env protein in established OC cell lines but not in
immortalized normal ovarian cell lines. FACS analysis further confirmed cell surface
expression by revealing greater surface expression of HERV-K env protein on established
OC cell lines but not in immortalized normal ovarian cell lines. We also confirmed HERVK SU env protein expression in ovarian tumor epithelial cells and correlated this significant
increase with tumor histotype. Finally, we ascertained that 55% of OC patient samples
(n=60) had positive titers for anti-HERV-K antibodies compared to only 5% of normal
female controls (n=20).
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Upon publication of this study, we were the first to report that HERV-K env protein
was expressed on the surface and in the cytoplasm of HERV-K-positive OC cells. Most
importantly, no expression was detected in normal or immortalized normal or immortalized
normal surface ovarian epithelial cells. The detection of anti-HERV-K antibodies in OC
patient sera samples showed a lack of tolerance and confirmed that OC patients possessed
the ability to mount an immune response against specific HERVs.

1.10 Mechanisms by which HERV-K is selectively expressed in ovarian cancer
The majority of HERV insertions are transcriptionally silenced in most embryonic
and adult tissues through repressive epigenetic marks 176 that are deposited and maintained
by the host surveillance system 177. Failure to maintain these marks results in the
reactivation of dormant HERV insertions 178. Dysregulated expression of HERVs may be
related to hypomethylation of HERV genes in tumor cells 179, 180, therefore the repressive
role of DNA methylation on HERV activity in human cells and tissues is being increasingly
studied. Epigenetic aberrations, including genome-wide hypomethylation, are crucial in the
development and progression of OC 181. In contrast to the overall DNA methylation
patterns observed in normal cells, a global hypomethylation of CpG dinucleotides in
combination with hypermethylation of CpG islands occurs in cancer 182. CpG islands tend
to associate with the promoters of housekeeping genes 183 and therefore their methylation in
malignancy causes repression of tumor suppressor genes 184. In contrast, DNA
hypomethylation renders HERVs transcriptionally active 10. HERV-K hypomethylation can
lead to several biological consequences including genomic instability 185, 186, aberrant gene
expression due to effects from LTRs 187, and cancer development via HERV RNA or
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proteins. Selective transcription of HERV-K could be explained by changes in tumorspecific transcription factors or tissue specific factors 188-190. Activation could also be
attributable to selective hypomethylation of these genes as seen with HERV-W in human
OC 180, 191, 192.
The expressions of HERV-K and HERV-E are increased in tissues from patients
with ovarian clear cell carcinoma (OCCC), a particular type of epithelial OC. Long
interspersed repetitive sequence-1 (LINE-1), a specific type of intersperse repetitive
sequence (IRS), is hypomethylated in most cancers including epithelial OC 193, 194.
Therefore in a recent study, Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat
S, Mutirangura A evaluated if the loss of DNA methylation of HERV sequences can be an
epigenetic signature to predict the prognosis and treatment response of OCCC 195. Indeed
they found that both HERV-K and HERV-E lose methylation during OCCC progression and
only HERV-K hypomethylation is significantly associated with poor survival and platinum
resistance195. Determining HERV-K methylation levels in OC before chemotherapy may be
critical for proper treatment plans in the future. Further studies must be conducted in order
to determine the mechanisms involved in HERV-K hypomethylation.

1.11 Mounting effective antitumor immunity
There are three distinct steps that must be achieved in order to mount effective
antitumor immunity. First, to initiate immunity, DCs must sample antigens derived from the
tumor such as mutated proteins typical of cancer, the products of non-mutated genes that are
preferentially expressed by cancer cells, or differentiation antigens associated with the
cancer’s tissue of origin 196, 197. Within the realm of therapeutic vaccines, these antigens are
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delivered exogenously. When a DC ingests this antigen, it will also require an activation
signal to differentiate and promote immunity 198, 199.
Secondly, tumor-antigen loaded DCs must generate protective T-cell responses in
lymphoid organs 200. The specific type of T-cell response needed for antitumor immunity is
unknown. However, it will unquestionably include CD8+ effector T cells with cytotoxic
potential. It is imperative that the DCs received the maturation signal at this point in order
to elicit the desired T cells, otherwise un-matured DCs promote tolerance by T-reg
production 201-204.
Finally, cancer-specific T cells must enter the tumor bed to perform their function.
Due to the complex tumor microenvironment, this step in antitumor immunity is a key
challenge. One major obstacle is local accumulation of T-regs that oppose the activity of
effector T cells. Tumors also have the ability to down-regulate their expression of MHC
class I molecules or their expression of target tumor antigens. Additionally, tumors can
produce surface molecules that engage receptors on the surfaces of activated T cells, causing
T-cell anergy or exhaustion 205, 206. Tumors can also release immunosuppressive molecules
limiting T-cell function 207, 208. Hypoxia in the tumor microenvironment may also inhibit Tcell function via the generation of adenosine 209. Finally, tumor stroma cells can suppress
the functions of T-cells by several methods 210.

1.12 Immunotherapy
Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an
immune response. There are two types of manipulation based on the functionality of the
patient’s immune system. If the patient’s immune system is functional, immunotherapy can
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be use d to activate or enhance the patients’ immune system via exposing patients to tumorassociated antigens displayed by their tumors. If the patient’s immune system is not
functional, passive immunization via introduction of antibodies or adoptive transfer of
immune cells needs to be employed. Cancer immunotherapy combines the specificity of
the adaptive immune system with the cytotoxic capabilities of both the adaptive and innate
immune systems. Immunotherapy strategies include the following: antitumor monoclonal
antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and natural killer cells,
and administration of antibodies or recombinant proteins with the potential to either
costimulate immune cells or block immune inhibitory pathways 211.
Tumor-specific monoclonal antibodies (mAb) have had a major impact on
immunotherapy. Numerous mAbs, including bispecific mAbs and multispecific fusion
proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized
pharmacokinetics, are in clinical trials. Importantly, it is the interaction between mAb and
Fc receptor (FcR) that contributes to the clinical antitumor activity of mAbs. For example,
changing the sequence or glycosylation of Fc regions can enhance interactions with FcR in
immune effector cells 212, 213. There are extensive interactions among various mechanisms
of action that modulate the immune effects of mAbs. Many studies have shown data
supporting the role of antibody-dependent cell-mediated cytotoxicity (ADCC) as a major
mechanism of mAb activity. Complement-mediated cytotoxicity (CMC) may contribute to
antitumor activity in solid tumors but there is little evidence. MAbs have shown great
promise and are currently the three top-selling cancer drugs. The majority of mAbs
approved for clinical used contain a human immunoglobulin (Ig) G1 heavy chain.
Trastuzumab is a recombinant humanized mAb that targets the HER2 receptor, inhibits cell
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proliferation and DNA repair, induces apoptosis, and promotes DNA damage and immune
modulation, thus causing cell-cycle arrest. This mAb has been approved by the US FDA for
the treatment of metastatic BC with HER2 overexpression. Cetuximab is a chimeric mAb
raised against epidermal growth factor receptor (EGFR) and inhibits endogenous ligands
binding, cell motility, invasiveness, metastasis, and the promotion of apoptosis 214.
Cetuximab is also FDA approved for treating advanced colorectal cancer and squamous cell
carcinoma of the head and neck. Bevacizumab is a humanized mAb that inhibits the
biological activities of vascular endothelial growth factor (VEGF) and blocks binding of
VEGF to its receptor on vascular endothelium. This mAb has been FDA approved since
2004 as first-line therapy in metastatic colorectal cancer.
The beauty of cancer vaccines is that they demonstrate minimal toxicity in
comparison to other forms of cancer therapy which kill tumor cells and normal cells alike.
However, the success of immunotherapy depends on overcoming several significant
barriers. First, tumor-associated antigens are typically closely related or identical to selfantigens, making unwanted autoimmune responses a risk. Secondly, the
immunosuppressive factors within the tumor microenvironment need to be avoided 215.
The idea of a therapeutic cancer vaccine originated with the discovery that patients
produce CD8+ and CD4+ T cells specific for antigens expressed in their tumors 196.
Common tumor-associated antigens include oncoproteins, oncofetal antigens,
differentiation-associated protein, viral proteins, and others. The goal of vaccination was
therefore to amplify the frequency and strength of these responses or induce new reactions.
Studies have shown a strong association between the presence of intratumoral CD3+ or
CD8+ cytotoxic T cells and the IFN-γ gene signature and prolonged patient survival 139, 216.
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This idea was an expedient one, however many initial attempts failed due to a poor
understanding of the immune system. Presently, the importance and function of DCs has
been determined to play a key role in improving therapeutic efficacy. A recent study of
peptides derived from the HPV-16 E6 and E7 viral oncoproteins showed clinical responses
in women with vulvar intraepithelial neoplasia due to the presence of HPV-specific IFN-γproducing CD4+ and CD8+ T cells 217. It is believed that these propitious results are due to
the fact that viral proteins are recognized as foreign by the host, leading to a stronger T-cell
response.
In comparison to peptides, full-length proteins contain a broader profile of epitopes
that might be presented by DCs and therefore may be more advantageous. It is known that
for a cancer vaccine to be efficacious, it must induce both antigen-specific CD8+ CTLs and
antigen-specific CD4+ cells, and protein-based vaccines usually contain both 165. Indeed, a
current randomize phase III trial using a recombinant fusion protein, MAGE-A3, an
adjuvant, and TLR4 and TLR9 agonists, has shown a survival response of 27% in HLA-A2positive non-small cell lung cancer patients 218.
Another vaccination strategy under evaluation involves viral vectors encoding tumor
antigens. These strategies exploit the fact that viral components elicit strong immune
responses. In a current phase II trial, recombinant vaccinia virus encoding prostate-specific
antigen and the adhesion molecules B7-1, ICAM-1 and LFA-3, were combined with GMCSF to produce a vaccine against prostate cancer. Positive results indicate an overall
survival benefit of 25.1 months versus 16.6 months in the control group 219.
Numerous preclinical studies have presented data on the enhanced antitumor
responses seen when vaccines are combined with inhibitors of immune suppression.
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Monoclonal anti-CD25-diptherial toxin (Ontak) has been shown to successfully reduce Tregs and to enhance vaccine efficiency 220, 221. Cyclophosphamide also reduces the number
of T-regs and their functionality, and has been shown to enhance vaccine efficacy in both
preclinical and clinical studies 222, 223. Both monoclonal and small molecule inhibitors to
TGF-β may have potential in vaccine combination therapy

224-227

.

1.13 Stem cells in ovarian cancer
Cancer stem cells are rare chemotherapy resistant cells within a tumor which can
serve to populate the bulk of the tumor with more differentiated daughter cells and
potentially contribute to recurrent disease 228. Within an OC, there are many unique cell
populations that each have different capacities for growth, survival, metastasis and
resistance to chemotherapy and radiation therapy 229, 230, however the exact phenotype and
characteristics of OC stem cells are still disputable 231. Cancer stem cells typically make up
0.01-1.0% of malignant cells within a tumor and have unlimited division potential. Based
on their resistance to traditional cancer therapies and presumed ability to recapitulate the
original tumor, cancer stem cells are believed to be the source of recurrent OC 228.
Therefore much effort has been given the characterization of these stem cells in order to
ultimately target them. One of the most widely known OC stem cell markers is CD133, a
membrane glycoprotein encoded by the CD133/Prom-1 gene. In a keystone article,
Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli
E, Rutella S, Paglia A, Zannoni G, Mancuso S, and Scambia G determined that primary OC
CD133+ cells had greater colony forming potential and higher proliferative potential than
CD133- cells 232. More importantly, they determined that normal ovaries and benign tumors
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had a significantly lower expression of CD133 than ovarian carcinomas. CD44, a receptor
for hyaluronic acid, has been identified as a marker of cancer stem cells in breast 233,
prostate 234, colorectal 235, pancreatic 236, head and neck squamous cell carcinomas 237. One
study analyzed tumor spheroids generated from the ascites of patients with serous ovarian
cancer 238. After ~10 serial passages in stem cell media, it was observed that the remaining
spheroid cells were highly enriched for CD44 expression, were resistant to chemotherapy,
and were able to initiate and serially propagate tumors in mice. These stem cells markers
represent potential therapeutic targets and may even be functionally important for stem cell
survival, making them even more attractive. One downside is that only 34-40% of ovarian
tumors express CD133 230, 232, 239. Also, CD44 may have a broad expression including
normal tissue. Therefore, targeting these stem cells with other types of tumor specific
markers has the potential to lead to localized therapeutic approaches but minimization of
systemic exposure needs to be optimized.

1.14 Project Overview
In our previous work, we were the first report expression of HERV-K env protein in
actual specimens of breast ductal epithelial tumors but not in normal breast in humans. We
also determined that HERV-K has great potential as a BC vaccine because it induced an
antigen-specific immune response in BC patients. Specifically, we showed that cytotoxic T
lymphocytes from cancer patients could lyse established BC cell lines expressing HERV-K.
At that time, only one other group had documented the presence of HERV-K-specific CTL
responses in human cancer 80. We then delved into another malevolent female cancer, OC,
and were the first to report that HERV-K env protein is expressed on the surface and in the
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cytoplasm of OC cells and that expression of HERV-K env mRNA was greater in ovarian
epithelial tumors than in normal ovarian tissues. Additionally, we confirmed that the
frequency of expression of HERV-K env protein in OC samples had a significant correlation
with tumor histotype. Finally we detected anti-HERV antibodies in patients with OC, but
not in normal female controls.
Based on our previous findings in BC and OC, our next goal was to reconfirm
HERV-K expression in OC and evaluate the effectiveness of HERV-K as a potential tumorassociated antigen for development of an OC vaccine by examining a new patient cohort
which included samples from OC patients, patients with benign disease and adjacent
uninvolved samples. We obtained several patients providing both tumor and adjacent
uninvolved samples, allowing an ideal situation to determine differences in HERV-K env
expression patterns and immune responses. Most importantly, we wanted to determine if
cytotoxic T cells from cancer patients could lyse autologous target cancer cells expressing
HERV-K while ignoring normal cells. Therefore, we hypothesize that HERV-K is a tumorassociated antigen and that there is selective expression and distribution of these elements in
OC, but not in benign samples or normal controls. We hypothesize that HERV-K env
protein, a retroviral antigen product, will be a safe and efficient candidate for development
of an OC vaccine.
Our first aim is to assess the expression profiles of HERV-K env proteins and antiHERV-K antibodies in primary OC, benign patient samples, and normal controls. To
achieve this goal we utilized a new patient cohort and determine expression of HERV-K env
mRNA and protein. We specifically determined cell surface expression of HERV-K env
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protein in primary samples from OC, benign and adjacent uninvolved tissues. We then
characterized the primary cells based on IF expression and stem cell markers. Next we
assessed whether activation of HERV-K correlates with clinical or histological
characteristics of OC patients. We also determined and compared levels of anti-HERV-K
Abs in OC and benign patient serum samples and correlated them with clinical
characteristics.
Our second aim is to evaluate the immune responses triggered by HERV-K antigen
in OC, benign patient, and normal donors. To achieve this we first characterized patient
samples to determine specific lymphocyte populations. Next, we determined changes in T
cell proliferation and IFN-γ secretion in OC patient lymphocytes compared to benign
samples, and normal donors. We also determined CTL activity using autologous OC,
benign, and adjacent uninvolved patient target cells. Finally we determined the effects T-reg
depletion on CTL activity.
The majority of current tumor-associated antigens represent self-antigens that have
become aberrantly expressed by the cancer. Therefore, the majority of solid tumors are not
immunogenic. Also, these antigens are sometimes expressed in normal tissues. Thus
immunotherapeutic techniques targeted against these antigens are impeded by the need to
overcome self-tolerance mechanisms that ultimately limit the immune response. Viral
antigens, on the other hand, are considered “foreign” to the body and might elicit stronger
antitumor T-cell responses. Therefore we believe that HERV-K, a novel tumor-associated
antigen, is an ideal target for immunotherapy in OC.
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Chapter 2. Materials and Methods

2.1 Human primary samples
Human ovarian tissues and peripheral blood mononuclear cells (PBMC) from OC
patients, patients with benign disease, patients with other cancers, or healthy female controls
were obtained from The MD Anderson Cancer Center according to approved Institutional
Review Board protocols. Age distribution and patient histological diagnoses are shown in
Figure 4.
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Figure 4: Ovarian patient age distribution. The age distribution of patients used in this
study.

39

Figure 5: Ovarian histological diagnoses distributions. Examples from each histological
category are listed. Surface epithelial tumors: papillary serous carcinoma, serous borderline,
Mullerian borderline tumor, metastatic adenocarcinoma, mucinous adenocarcinoma. Germ
cell tumors: teratoma. Benign disease: endometriotic cyst, benign cyst, follicular cysts.
Other cancer: gastrointestinal stromal tumor, neuroendocrine tumor, gallbladder
adenocarcinoma. Other: endometriosis, fibrotic tissue with inflammation.
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2.2 Established cell lines
OVCAR3, SKOV3, DOV13 human epithelial OC established cell lines were
obtained from ATCC (Rockville, MD). Cells were grown in Dulbecco’s modified eagle
media (DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin and 1%
Glutamax.

2.3 Harvesting of primary tissue samples
A piece of tissue in 1-2 ml of cold complete NOE culture medium (250 ml of
Medium 199+ 250 ml DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin
and 1% Glutamax, was added to a Petri dish and chopped into small pieces with a razor
blade to obtain a thick soup of tumor cells/pieces. 20X the volume of cold medium was
added, inverted to mix, and spun at 900 rpm for 5 minutes. The tissue pieces and
dissociated cells pelleted, while the debris remained in the supernatant. The supernatant was
removed and the cells were resuspended in Accumax solution at a concentration of 10
ml/0.5 g of tissue and incubated at room temperature for 60 minutes on a shaker. The cells
were washed with 1xPBS, resuspended in 20 ml of media, and transferred to a Stomacher 80
bag. The bag was inserted into the Stomacher (Seward Co.) and run for 15 minutes at high
speed. The mixture was transferred to a 50 ml tube and the larger chunks were allowed to
settle to the bottom. The supernatant containing the dissociated cells was transferred to a
fresh tube, spun at 900 rpm for 5 minutes, and resuspended in 1-3 ml medium. The cells
were then passed through a 40µm nylon mesh into a 50 ml tube. The live cells were then
separated from dead cells, debris, and red blood cells via the use of a Ficoll-1077 gradient.
The cells were spun on Ficoll-1077 at 400g for 30 minutes at room temperature and the
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opaque layer of cells at the interphase of the two layers was transferred to a new tube. The
cells were spun at 900 rpm for 5 minutes, resuspended in low serum NOE media to and
plated in a 6-well low adherent plate. To culture tumorspheres, 6-well plates were coated
with 1 ml of 0.8% agarose 240, and cells were added in 2 ml per well of Mammocult media
supplemented with heparin and hydrocortisone.

2.4 RT-PCR
For tissue samples obtained at the MD Anderson Cancer Center, RNA isolation and RTPCR were employed as described previously 67, 68. Briefly, total RNA was isolated from
primary cell lines in Tri-reagent according to the manufacturer’s instructions and treated
with RNase-free DNase I at 37°C for 30 minutes to prevent contamination of genomic DNA.
RNA was then incubated at 75°C for 5 minutes to inactivate residual DNase. A first strand
cDNA was synthesized from the RNA template using Ready-To-GoTM You-Prime FirstStrand Beads. 10µg RNA was added to 32µl of diethylpyrocarbonate (DEPC)-treated H2O
and incubated at 65°C for 10 minutes. Following this incubation, 1 µl of random primers
were added to the RNA solution and then incubated again with the beads at 37°C for 1 hour.
3.3µl of cDNA, corresponding to 1 µg of RNA, was incubated with 5 µl of 10x PCR buffer,
0.25 µl of Taq DNA polymerase, and the various primer pairs. Primers used for RT-PCR
included HERV-K SU env type 1 and type 2 primers, HERV-E env primers, ERV-3 primers,
and β-actin primers, which were described previously 175. No template and β-actin were used
as negative and positive controls, respectively. The HERV-K env PCR primers were
designed by Sangon Biotech Co. Ltd. (Shanghai), and produced by Takara Biotechnology
Co. Ltd. (Dalian), according to the HERV-K102 env sequence (GenBank accession no.
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AF164610.1). After the initial denaturation step at 94°C for 3 minutes, 30 cycles of
amplification were performed as follows: denaturation at 94°C for 1 minute, annealing at
55°C for 1 minutes, and extension at 72°C for 1 minute. The RT-PCR product was then
subjected to electrophoresis on a 1% agarose gel by ethidium bromide staining to confirm
size.

2.5 Synthesis of HERV-K env fusion proteins and antibodies and cRNA
HERV-K env surface fusion proteins were expressed from the pGEX-6p1 plasmid
(K10G17) in Escherichia coli (E.coli) BL-21(DE3) or from the pQE30 plasmid (K10Q18) in
E. coli M15 by incubating at 18°C overnight in the presence of ampicillin (100 µg/ml),
kanamycin (25 µg/ml), and 1 mmol/L isopropyl-L-thio-B-D-galactopyranoside until an
OD600 of 0.8 was reached. To express the TM fusion protein, a recombinant pQE30-TM
bacterial clone was grown in an identical manner. Bacterial pellets were harvested,
disrupted by lysozyme treatment followed by sonication, clarified by 0.2 µm filtration, and
affinity purified with glutathione-Sepharose FF using an ÄKTA fast protein liquid
chromatography (FPLC; GE Healthcare). The purified K10Q18 fusion proteins were then
used to immunize 6- to 8-week-old BALB/c mice. Hybridoma cells were derived from the
splenocytes of immunized mice by fusion with a myeloma cell line using standard
techniques, as described previously 175, 241. Several monoclonal antibodies against HERV-K
env SU protein were generated in our laboratory and ELISA and immunoblot screening
revealed that mAb 6H5 had the highest specificity and sensitivity toward HERV-K. 6H5
hybridoma ascites was then collected from pristane-primed mice, precipitated twice with
saturated ammonium sulfate, clarified by 0.2 µm filtration, and affinity purified with protein
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G-Sepharose HP by FPLC. The eluate fractions containing 6H5 mAb were dialyzed against
PBS, concentrated, and filter sterilized before testing. 6H5 antibody was labeled with Alexa
Fluor® dyes 647 and 488 to be used in FACS analysis and IFS respectively. Keyhole limpet
hemocyanin (KLH) protein (Pierce) was used as a negative control throughout our
experiments. Several experiments utilized the human papillomavirus E6 protein as a
negative control. HERV-K and E6 cRNA were produced by in vitro transcription 67.

2.6 ELISA
100 µl of diluted KSU protein (10 µg/ml) was added to each well of a flat-bottom 96
well plate, and incubated overnight at 4°C. Plates were washed 6 times with 1xPBS, 100 µl
of blocking buffer (1xPBS+1% BSA) was added to each well, and plates were incubated at
room temperature for 60 minutes. Blocking buffer was removed by flipping the plate over
and tapping it on a paper towel. E. coli lysate was added to serum samples at a 1:20 dilution
and the mixture was incubated for 30 minutes at room temperature. Human patient serum
was then added in the correct dilution to triplicate wells and plates were incubated overnight
at 4°C. Plates were washed 6 times with 1xPBS, 100 µl of mouse-IgG-HRP (1:4,000
dilution in 1xPBS) secondary antibody was added to each well and incubated for 60 minutes
at room temperature. Plates were again washed 6 times with 1xPBS and 100 µl of ABTS
substrate solution (200 µl ABTS and 10 µl 30% H2O2 in 10 ml citrate buffer) was added to
each well. The absorbance was measured with a Wallac VICTOR2 plate reader (Perkin
Elmer) at 405 nanometers at different time points. The ELISA was performed in triplicate
for each dilution.

44

2.7 FACS
1 x 106 cells/well were added to a round-bottomed 96-well plate and labeled with 1
µg/well of primary antibody diluted in BD Stain Buffer (BD Biosciences) for 60 minutes at
room temperature. After washing cells twice with 1xPBS, samples were incubated with
secondary Alexa Fluor 647 conjugated mouse-IgG for 30 minutes at room temperature.
After washing cells twice with 1xPBS, samples were resuspended in 250 µl 1xPBS and
analyzed by a BD FACsArray (BD Biosciences).

2.8 QIFIKIT
QIFIKIT (Dako) was used for the quantitative determination of cell surface HERV-K
antigen by flow cytometry using an indirect immunofluorescence assay. 1 x 106 human
patient ovarian cells/well were added to a round-bottomed 96-well plate and labeled with
6H5 mAb at saturating concentration. The cells were incubated, in parallel with the
QIFIKIT® beads, with secondary Alexa Fluor 647 conjugated mouse IgG at saturating
concentration. A calibration curve was constructed by plotting the fluorescence intensity of
the individual bead populations against the number of mAb molecules on the beads. The
number of antigenic sites on the specimen cells was then determined by interpolation.

2.9 Immunofluorescence (IFS)/Fluorescence Microscopy/Confocal Microscopy
5x105 cells/well were seeded onto glass coverslips in a 6-well plate and incubated at
37°C overnight. The media was removed and cells were fixed with fresh 4%
paraformaldehyde for 20 minutes at room temperature. Cells were blocked in 3% BSA
blocking buffer for 60 minutes at room temperature, and then incubated with primary
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antibody for 60 minutes at 37°C. After washing cells twice with 1xPBS, samples were
incubated with secondary Alexa Fluor 488 conjugated mouse IgG for 30 minutes at 37°C.
After washing cells twice with 1xPBS, cellular nuclei were stained with DAPI for 3 minutes
at room temperature, and then washed again with deionized H2O. Coverslips were added to
the slides with 90% glycerol in water and examined under either an Olympus IX51
fluorescent microscope with a DP70 camera, or a laser-scanning confocal microscope (Zeiss
510 Meta) with appropriate filters.

2.10 Immunohistochemical analysis (IHC)
Immunohistochemical analysis was performed on tissue slides using an LV-1
Autostainer universal staining system (Dako) in combination with the VECTASTAIN ABC
system and DAB kit (Vector). Slides were baked in an oven at 60ºC for 1 hour and then
removed to cool. Slides were placed on an Autostainer to deparaffinize and hydrate tissue
sections through xylenes and a graded alcohol series. A circle was drawn with a wax pencil
around the section of tissue. Peroxidase blocking solution (3% H2O2) was added to each
slide and incubated at room temperature for 10 minutes. The slides were washed for 5
minutes in H2O. Blocking solution was added (AB serum (2% solution in 1XPBS), goat
serum (2% solution in 1XPBS plus 3% BSA) to slides and incubated at room temperature
for 30 minutes. The solution was tipped off without rinsing and 150 µl of diluted 6H5 mAb
in 1 ml of blocking solution was added to each section. The slides were placed into a
humidified chamber and place in a 4ºC cold room for 16 hour. Slides were washed three
times with 1XPBS for 30 minutes each in a glass container with a stir bar. Sections were
incubated for 30 minutes with mouse-IgG-HRP (1:600 dilution in blocking buffer)
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secondary antibody and then washed three times with 1XPBS for 30 minutes each in a glass
container with a stir bar. Sections were incubated in DAB for 5 minutes and then washed in
H20 to stop the DAB reaction. Slides were counterstained with hematoxylin for 8 minutes,
washed thoroughly in H20, and placed in the Autostainer through a graded alcohol series and
xylenes. Cover slips were added with Permount, and samples were examined under a
microscope Axiovert 200 (Carl Zeiss MicroImaging, Thornwood, NY).

2.11 Peripheral blood mononuclear cell (PBMC) isolation from human blood samples
PBMCs were isolated from whole blood samples by density gradient
centrifugation using Ficoll-1077 (Sigma, St. Louis, MO). Briefly, 10 ml of blood from a red
Vaccutainer tube was spun down at 2,000 rpm for 5 minutes at room temperature, and the
serum layer was removed and stored at -80°C for future analysis. 10 ml of blood from a
sodium heparin green Vaccutainer tube was transferred to a 50 ml Falcon tube and spun
down at 2,000 rpm for 5 minutes at room temperature. The upper plasma layer was removed
and stored at -80°C for future analysis. 1xPBS was added to the remaining blood to reach a
final volume of 40 ml. The diluted blood was then very slowly added to a 50 ml Falcon tube
previously loaded with 10 ml Ficoll-1077. The tubes were spun down at 1,500 rpm for 30
minutes at room temperature using slow acceleration and deceleration rates. PBMCs were
recovered by collecting the Ficol-1077 and 1xPBS layers without disturbing the pellet of
erythrocytes and granulocytes and placing them in a new 50 ml tube. The cells were washed
by adding 30 ml PBS and spun down at 2,000 rpm for 10 minutes at room temperature. The
supernatant was discarded, 5 ml of RBC Lysis Solution (8.3g NH4Cl, 1.0g KHCO3, and 1.8
ml of 5% EDTA in 1L distilled H2O) was added to the cells and the mixture was incubated
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for 5 minutes at room temperature. After washing three times with 1xPBS,
PBS, the PBMCs were
resuspended
suspended in complete RPMI 1640 culture medium at 2×106/ml, seeded in
n a 6-well
6
plate,
and placed in a 37°C incubator overnight for DC preparation.

2.12 Preparation of dendritic cells
PBMCs were plated at a density of 2x106 cells/well in a 6-well
well plate and incubated
for 16 hours at 37°C. Warm media was carefully added and used to wash the cells three
times. The non-adherent
adherent cells were pelleted and frozen back for future assays. The
remaining adherent cells were incubated for 6 days with granulocyte macrophage colonycolony
stimulating factor (GM-CSF)
CSF) and in
interleukin (IL)-4 (1,000 units/ml)) (R&D Systems). The
immature DCs were harvested and transfected with K
K-SU or KLH protein using the
BioPORTER lipid-based transfection reagent per the manufacturer’s instructions. After four
hours, tumor necrosis factor-- (TNF- ) (1,000 units/ml) was added for 16 hours at 37°C to
induce DC maturation.

2.13 Preparation of IVS cells
PBMCs (1 x 106/ml)) were added to autologous HERV-K protein transfected matured
DC at a DC to PBMC ratio of 1:30 on day 0. Cultures were cultured in AIM V medium
supplemented with 5% human Ab serum and IL-2 (100 units/ml) for 7 days to generate 1week IVS cells.
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2.14 T-cell
cell proliferation assay
T-cell
cell proliferation was evaluated in patient PBMC or IVS cells by restimulation for
72 hours with DC pulsed with no added protein, K
K-SU
SU protein, or KLH control protein, at a
DC to PBMC or IVS ratio of 1:30. After 72 hours of incubation, the supernatants were
collected and frozen for future cytokine secretion assays. The remaining cells were pulsed
with 1 µCi /well of [3H]thymidine and incubated for another 18 hhours at 37°C. Cells were
then harvested onto filter papers, tr
transferred to scintillation vials with scintillation fluid, and
analyzed on a beta counter.

linked immunospot assay
2.15 Enzyme-linked
An IFN-

enzyme-linked
linked immunospot (ELISPOT) assay to measure cytokine-

secreting cells in response to antigen was performed using a commercial kit (Biosource
International). ELISPOT plates were coated with 10 µg/ml of purified anti-human
human IFN-γ
IFN
capture antibody and incubated for 24 hhours at 4°C. Plates were then blocked for 2 hours
h
with complete media and PBMC or IVS cells were plated at 1 x 105 per well with DCs
pulsed with various HERV-K
K antigens plated at 5 x 103 per well. Plates were incubated for
24 hours at 37°C and then washed and incubated with the detection antibodies for 2 hours
h
at
25°C. Plates were washed and incubate
incubated
d with streptavidin horseradish peroxidase for 2
hours at 25°C. Plates were washed again and developed by adding 5-bromo--4-chloro-3indolyl-phosphate/nitro
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate solution and incubating for
10 to 60 minutes at 25°C until the desired color appeared
appeared.. Plates were washed thoroughly
with water, allowed to dry, and spots were counted using an ELISPO
ELISPOT
T reader (C.T.L.
Technologies).
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2.16 CTL assay
CTL assays were performed in round-bottomed 96-well plates using a standard 4hour 51Cr-release assay 242. Human primary tumor or benign cells lines (target cells) were
pulsed with HERV-K or KLH control protein for 16 hours at 37°C using the BioPORTER
transfection reagent described previously. Target cells were removed from flasks via EDTA
buffer, pelleted and resuspended in 500 µl media and 75µCi of chromium. After incubating
for 2 hours at 37°C, cells were washed with media 3 times and radioactive waste was
discarded properly. 5 X 104/ml target cells were then resuspended in media. 5 X 106/ml
autologous PBMCs or IVS cells (effector cells) were also resuspended in media. The
effector cells and target cells were then combined in the plates and incubate for 4 hours at
37°C. Effector to target cell ratios were plated at 100:1, 50:1, 25:1, and 12.5. The plates
were pelleted and supernatants (100 µl) from each well were removed and counted in a
gamma counter. After effector and target cells are incubated for 4 hours, the amount of
chromium release due to cell lysis is measured with a gamma counter. % specific lysis was
calculated by the following equation= ((Experimental value-minimum lysis)/(maximum
lysis-minimum lysis)) x100. Labeled target cells in media served as the minimum lysis
value and labeled target cells in % Triton X100 served as the maximum value.

2.17 Isolation of CD4+CD25+CD127dim/– regulatory T cells
The CD4+CD25+CD127dim/– Regulatory T Cell Isolation Kit II (Miltenyi Biotec) was
used to isolate T-regs. PBMCs were pelleted and resuspended in 40 µl of buffer consisting
of phosphate-buffered saline (PBS), pH 7.2, containing 0.5% bovine serum albumin (BSA),
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and 2 mM EDTA per 1 x 106 cells. 10 µl of CD4+CD25+CD127dim/- T Cell BiotinAntibody Cocktail II was added to the cell suspension and incubated for 10 minutes at 4ºC.
30 µl of buffer and 20 µl of Anti-Biotin Microbeads were added to the cell suspension and
incubated for 15 minutes at 4ºC. Cells were washed by adding 2 ml of buffer, pelleted, and
resuspended in 500 µl of buffer. An LD Column was placed in the magnetic field of a
MACS Separator and 2 ml of buffer was added to rinse the column. The cell suspension
was applied to the column and the pre-enriched CD4+ unlabeled cells that passed through the
column were collected. Cells were pelleted, resuspended in 90 µl of buffer plus 10 µl of
CD25 MicroBeads II, and incubated for 15 minutes at 4ºC. Cells were then washed by
adding 2 ml of buffer, pelleted, and resuspended in 500 µl of buffer. A MS Column was
placed in the magnetic field of a MACS Separator and 500 µl of buffer was added to rinse
the column. The cell suspension was applied to the column and unlabeled cells that passed
through were collected. The column was removed from the separator and placed into a
sterile collection tube. 1 ml of buffer was placed on the column and magnetically labeled
cells were flushed out by pushing a plunger into the column.

2.18 Apoptosis Assay
Annexin V staining precedes the loss of membrane integrity which characterizes the
later stages of cell death, and therefore the vital dye 7-amino-actinomycin D (7-AAD), in
conjunction with annexin V, was used to allow discrimination of early apoptotic cells. To
measure the effects of 6H5 mAb on cellular apoptosis in vitro, ovarian cells DOV13,
OVCAR3, and SKOV3 (5 x 105 cells/ml) were grown in their respective media and treated
with 6H5 mAb or control mouse-IgG antibody at a concentration of 10 µg/ml at 37oC for 16
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hours. Treated cells were harvested and resuspended in 200 µl 1× binding buffer (BD
Pharmingen) at 1 × 106 cells per well. Cells were stained with annexin V-allophycocyanin
(APC) (BD Pharmingen) at room temperature for 15 minutes followed by one wash with 1 ×
annexin V binding buffer. Cells were then incubated with 7-AAD-phycoerythrin-cyanide 7
at room temperature for 10 minutes, and samples were analyzed on a BD FACSArray
Bioanalyzer. The percentage of annexin V-positive cells for each cell line treated with 6H5
mAb was determined using FlowJo software (Version 7.2.5).

2.19 Statistical analysis
Analyses were done using GraphPad Prism version 5. Statistical significance of
differences between groups was determined by a Student's t test or a Chi-square test. A P
value <0.05 is considered to be statistically significant. Adjusted residual analysis, Z-test,
and Chi-squared test were used in IHC data analysis.
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Chapter 3: Results

3.1 Expression of HERV-K env mRNA in OC, benign and adjacent uninvolved patient
tissue samples
To investigate the expression of HERV-K env transcripts in patient tissue samples,
RT-PCR analysis was performed using an HERV-K env SU primer pair, amplifying a 1,105
bp DNA product. HERV-K type 2, was also amplified resulting in a 1,195 bp DNA product.
HERV3 (1,745 bp) and HERV-E41 (1,349 bp) primer pairs amplifying other HERV families
were used as negative controls and amplification of β-actin was used as a positive control.
Once the RT-PCR products were run an agarose gel, band intensities were based on the
following scale: +++ represent very intense bands, ++ represent strong bands, + represent
average to weak bands, and – represents no bands seen. Overall, the expression of HERV-K
env mRNA was assessed in cancer samples (n=29) and benign samples (n=17). Some of
these samples originate from patients with both cancer and uninvolved or benign specimens.
Representative gel documentation of RT-PCR products from particular patients is seen in
Figure 6 depicting these band intensities. In the OC samples tested, 7 (24.14%) samples
displayed an HERV-K band with +++/++ intensity, 13 (44.83%) with + intensity, and 9
(31.03%) with – intensity. In comparison, in the benign or adjacent uninvolved samples
tested, only 1 (5.88%) sample displayed an HERV-K band with +++/++ intensity, 3
(17.65%) with + intensity, and the majority 13 (76.47%) with – intensity. RT-PCR products
for HERK-type 2 and HERV3 had varying results with no trend seen. The majority of
patients tested had HERV-E41 bands with – intensity. As seen in the gel documentation, a
patient diagnosed with a benign cyst produced an HERV-K band of – intensity. Another
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patient diagnosed with papillary serous carcinoma produced an HERV-K band of +
intensity. Patients #103 and #65, both diagnosed with metastatic carcinoma, produced
HERV-K bands of ++ and + intensities respectively. Of great importance, mRNA from
autologous tumor and benign samples showed higher expression in the tumor sample
compared to the benign sample. Similarly, mRNA from autologous tumor and adjacent
uninvolved sample showed a higher expression in the tumor sample compared to the
adjacent uninvolved. We conclude that gene expression of HERV-K was higher in OC
tissue samples in comparison to benign and uninvolved samples.
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Figure 6: HERV env mRNA expression in OC, benign and adjacent uninvolved biopsies
via RT-PCR. Each set of lanes for a given amplified gene represents the RT-PCR
expression pattern using HERV-K Type 1 (HERV-K(1)), HERV-K Type 2(HERV-K(2)),
ERV3, HERV-E and β-actin primers. Gel documentations of various samples are seen on
the left. Of great importance, among tissue pairs from the same patient, HERV-K
expression is seen in tumor but not in benign tissue. A table at the bottom summarizes the
data from RT-PCR assays indicating that a significantly greater number of cancer samples
had +++/++ and + designations when compared to benign samples. Benign samples had a
statistically greater number of samples with – designations when compared to cancer
samples. Black arrows represent tissues derived from the same patient. A Pearson's chisquared test was used to calculate significance.
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3.2 Expression of HERV-K env protein in primary samples from OC, benign and
adjacent uninvolved tissues
After detecting HERV-K genes at a higher transcriptional level in OC samples
compared to benign and adjacent uninvolved samples, we next inquired whether HERV-K
SU envelope protein was expressed in primary samples. To accomplish this, we used a
monoclonal anti-HERV-K antibody (6H5 mAb) made using a standard hybridoma
technology, as described in the Materials and Methods section, to label the cellular
distribution of viral components via IHC. Representative images from various patient
tissues are shown in Figure 7. Positivity is shown by the brown chromagen deposits in the
images. IHC data from the tissues (n=406) show that HERV-K env expression is confined
to the outer layer and to the cytoplasm in OC samples such as endometrioid adenocarcinoma
and serous adenocarcinoma. No staining is seen in benign cysts or adjacent normal tissues.
This data is in agreement with the RT-PCR data. We did not find a statistically significant
association between envelope expression and patient age at diagnosis, race or ethnicity,
disease stage or grade, or node-positive status. Statistical data is presented in Table 2.
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Figure 7: HERV-K env protein expression in OC, benign and adjacent uninvolved biopsies
via IHC. Examples of immunostaining of endometrioid adenocarcinoma (A, B, C, and D),
serous adenocarcinoma (E, F, G, and H), benign cyst (I and J), and normal epithelium
biopsies (K and L) with 6H5: HERV-K+ cancer cells were detected in endometrioid
adenocarcinoma (C and D) and serous adenocarcinoma (G and H). HERV-K expression
was not detected in benign cysts or normal epithelium biopsies. The left column represents
40X and right column represents 10X power. The bottom table depicts statistical data for the
samples (n=406) screened.

57

Value

df

Asymp. Sig. (2-sided)

a

Pearson Chi-Square

8.134

3

0.043

Likelihood Ratio

8.840

3

0.032

N of Valid Cases

406

Table 2: The expression profile of HERV-K in ovarian tissues using anti-HERV-K monoclonal Ab
(6H5). Statistical data corresponding to IHC data. Adjusted residual analysis, Z-test, and Chi-

squared test were used for statistical analysis.
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3.3 Cell surface expression of HERV-K env protein in primary samples from OC,
benign and adjacent uninvolved tissues
Next, we wanted to expound on the translational data and confirm HERV-K
expression on the cell surface. To accomplish this, we used 6H5 mAb to label the cellular
distribution of viral components via IFS and subsequent confocal microscopy. We first
detected surface and cytoplasmic expression of HERV-K env protein in the established
human OC cell line, DOV13. The confocal image in Figure 8 confirms that indeed HERVK expression is seen on the surface and in the cytoplasm of these cells. FACS data
presented in Figure 9 confirms this data, indicating 53% of the cell population is positive for
surface and 86% of the cell population is positive for cytoplasmic expression of HERV-K.
We next focused on HERV-K protein expression in our primary cell lines. Figure 10
presents confocal images of OC cells obtained from a patient diagnosed with serous
carcinoma. The images show that HERV-K env expression is confined to the cell surface.
In contrast, Figure 11 presents images of adjacent uninvolved cells derived from a patient
diagnosed with mullerian borderline tumor with isolated foci of invasion. HERV-K env
expression on the cell surface is not observed in these cells. This data also confirmed that
activation of HERV-K indeed correlates with clinical or histological characteristics of OC
patients. This data is in accordance with the previous RT-PCR, IHC, and FACS data.
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Figure 8: Detection of surface (Non-perm) and cytoplasmic (Perm) expression of HERV-K
env protein in the established OC cell line, DOV13, via IFS and confocal microscopy.
DOV13 cells were EDTA-digested, pelleted on grown on glass coverslips overnight at 37°C.
Cells were either permeabilized with FACS permeabilization buffer or fixed with FACS
fixation buffer and then labeled with 6H5 antibody followed by an anti-mouse-IgG Alexa
Fluor 488 conjugated antibody. Confocal microscopy images show both surface and
cytoplasmic expression of HERV-K.
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Figure 9: Detection of surface (Non-perm) and cytoplasmic (Perm) expression of HERV-K
env protein in the established OC cell line, DOV13. DOV13 cells were EDTA- digested,
pelleted and either permeabilized with FACS permeabilization buffer or fixed with FACS
fixation buffer and then labeled with 6H5 antibody followed by an anti-mouse-IgG Alexa
Fluor 647 conjugated antibody. FACS analysis on 6H5 conjugated to Alexa Fluor 647
labeled DOV13 cells reveals both surface (blue line) and cytoplasmic (red line) HERV-K
expression.
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Figure 10: Detection of surface expression of HERV-K env protein in primary OC cells by
IFS and subsequent fluorescent microscopy. Pt#222 was diagnosed with serous carcinoma.
After tissue harvest, cells were plated and allowed to expand. Cells were EDTA-digested,
pelleted, and grown on glass coverslips. Cells were then fixed and labeled with 6H5
antibody, followed by anti-mouse-IgG Alexa Fluor 488 conjugated antibody. Fluorescent
images depict surface expression of HERV-K in these OC patient primary cells. Cells
labeled with only the secondary anti-mouse-IgG Alexa Fluor 488 conjugated antibody were
used as a negative control.
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Figure 11: Detection of surface expression of HERV-K env protein in primary OC cells by
IFS and subsequent fluorescent microscopy. Tumor and adjacent uninvolved tissue were
harvested from #105, diagnosed with mullerian borderline tumor with isolated foci of
invasion. Cells were EDTA-digested, pelleted, and grown on glass coverslips. Cells were
then fixed and labeled with 6H5 antibody, followed by anti-mouse-IgG Alexa Fluor 488
conjugated antibody. Images of tumor cells depicts cell surface staining for HERV-K.
Images of adjacent uninvolved cells depict no surface expression of HERV-K in these cells.
Cells labeled with only the secondary anti-mouse-IgG Alexa Fluor 488 conjugated antibody
were used as a negative control.
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3.3 Primary patient cell characterization
Recent studies have shown that non-neoplastic cells, notably the stromal cells of
human carcinomas, are active and essential collaborators with neoplastic epithelial cells
within tumor masses.

The diverse stromal cell types within tumors are all members of

several mesenchymal cell lineages that generate both connective tissue and immune cells
and are biologically very different from epithelial cells whose transformation drives the
growth of carcinomas243. For decades, intermediate filament proteins have been used as
molecular markers in diagnostic histopathology 244-246, and evidence suggests that aberrant
expression of individual cytokeratins or vimentin results in abnormal cell behavior 247.
Indeed it has been determined that epithelial and mesenchymal cells undergo dramatic
changes in their cytoskeletal scaffolds during tumorigenesis.
Vimentin is the main intermediate filament (IF) protein in mesenchymal cells 248, and
maintains cytoarchitecture and tissue integrity 249, 250. However, a growing body of evidence
has focused on the role of vimentin in cell migration and epithelial-mesenchymal transition
of epithelial carcinomas 248. Studies of human epithelial carcinoma cell lines have
demonstrated that vimentin expression is induced in invasive cells lines 251-253 and in BC, its
expression is correlated with poor prognosis 254. Also, studies have proven that occurrence
of metastasis in hepatocellular carcinoma is significantly associated with over-expression of
vimentin 255. In a recent study, Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR,
Giordano TJ, Shedden KA, Misek DE, and Lubman DM compared protein expression in
low stage (Stage 1) versus high stage (Stages 3/4) ovarian serous adenocarcinomas and
determined that vimentin was significantly overexpressed in the high stage tumors as
compared with the low stage 256. It is unknown whether vimentin expression is a marker for
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epithelial-mesenchymal transition (EMT)-like changes or if vimentin expression is required
for the invasive behavior of cells 248.
Cytokeratins are keratin-containing intermediate filaments found in the
intracytoplasmic cytoskeleton of epithelial tissue. Cytokeratins are composed of a family of
at least 20 different polypeptides and are distributed in both normal and neoplastic tissues
244

. Epithelial ovarian tumors are thought to arise from the ovarian surface epithelium and

contain cytokeratins 7, 8, 18, and 19 257. However, loss of cytokeratin expression has been
found to occur in the primary tumors and is associated with factors predictive for an
unfavorable prognosis for patients with BC. In one study, IHC analysis of BC tissues
showed that reduced cytokeratin 18 expression was correlated with poor clinical outcome
258

. Also, down-regulation of cytokeratin 19 expression and overexpression of vimentin

were found in highly aggressive BC cell lines exhibiting strong migratory and invasive
abilities 259. Loss of cytokeratin 8 and 18 expression and concurrent up-regulation of
vimentin has also been found to suggest that disseminated tumor cells have acquired a
mesenchymal-like, aggressive phenotype 247. Alternatively, numerous others studies have
shown that coexpression of vimentin and cytokeratin correlates with invasiveness and
metastasis 260-263.
Thus, our next goal was to characterize the primary cells harvested and used in our
experiments to determine populations of epithelial and mesenchymal cells and changes in
cytoskeletal scaffolds. We therefore employed the following antibodies: anti-vimentin to
identify cells of mesenchymal origin, anti-pan cytokeratin to identify epithelial cells, and
anti-NCL-L-5D3 (cytokeratin 8 and 18) to identify tumor epithelial cells. After labeling the
primary cells, we analyzed them via FACS and confirmed these results visually via confocal
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microscopy. Table 3 lists the percentage of cells positive for the respective antibody used in
both tumor and benign samples. As seen in Figure 12, there is positive staining for both
cytokeratin for both OC and benign samples indicating the presence of epithelial cells.
Positive staining is also seen for vimentin for both OC and benign samples indicating
mesenchymal cells or cells undergoing epithelial-to mesenchymal transition. Both benign
and OC samples stained positively for NCL-L-5D3 indicating the presence of tumor
epithelial cells. This positive co-expression of cytokeratin and vimentin corresponds to
results from other studies discussed previously. Patient #65 diagnosed with metastatic
adenocarcinoma displayed very high coexpression of cytokeratins and vimentins which
correlated with the cell’s strong migratory and invasive behavior.
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Table 3: Primary cell line characterization: Epithelial, mesenchymal, and tumor epithelial
cell populations via FACS. After harvesting patient tissues and culturing cells, samples
were characterized via FACS. Cells were stained with anti-vimentin, anti-pan cytokeratin,
and anti- NCL-L-5D3 antibodies and subjected to flow cytometry analysis. Percentages
indicate populations of cells positive for the respective antibody used.
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Figure 12: Primary cell line characterization: Epithelial and mesenchymal cell populations
via IFS and confocal microscopy. Benign cells from #144 diagnosed with benign disease
and tumor cells from #222 diagnosed with serous carcinoma are shown. Human primary
cells were characterized approximately 4 days post-harvest to determine specific cell
populations. Cells were grown on glass coverslips, fixed, and labeled with anti-cytokeratin
and anti-vimentin followed by a secondary anti-mouse IgG Alexa Fluor 488 conjugated
antibody. Secondary antibody only was used as a negative control and indeed no staining is
seen. The figure shows positive staining for cytokeratin for both OC and benign samples
indicating the presence of epithelial cells. Positive staining is also seen for vimentin for
both OC and benign samples indicating mesenchymal cells or cells undergoing epithelial-to
mesenchymal transition.
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3.4 Individual cases of patient characterization
We next focused our attention on an OC patient diagnosed with metastatic
adenocarcinoma. Figure 13 depicts cultured ascites cells from this patient one day postharvest in 2-D culture to display cell morphology. These cells are morphologically similar
to epithelial cells and not stromal cells which are classified by a cell body and cell processes
that are long and thin. After harvesting the ascites on day 0, we cultured cells on 0.8%
agarose plates in serum-free Mammocult media in order to support stem cell populations.
These cells were then termed “tumorspheres” as their appearance was of suspended spheres.
RT-PCR data for this patient at both time points, asserts expression of mRNA HERV-K type
1 and type 2 transcripts, and ERV-3 transcripts. However, expression is clearly increased
after tumorsphere culture. Expression of HERV-E41 transcripts are seen after tumorsphere
culture. Figure 14 displays a QIFIKIT assay employed in order to quantify the number of
HERV-K surface molecules on ascites cells one day post-harvest. 164,528 HERV-K
molecules were determined to be expressed on the cell surface. Finally, Figure 15 reveals
FACS analysis of tumorspheres confirming HERV-K, epithelial, mesenchymal and
epithelial cancer cell positivity after staining with 6H5 mAb, anti-vimentin, anti-cytokeratin,
and anti-NCL-L-5D3 antibodies at 1 day and 7 days post-harvest. After tumorsphere
culture, populations of cytokeratin, vimentin, tumor epithelial, HERV-K positive
populations increased. We are also very interested in determining OC stem cell
populations. Therefore, we stained cells with anti-CD133 and anti-CD44 cancer stem cell
markers. FACS analysis shows that populations of cells positive for CD44 increased, but
CD133 positive populations decreased slightly.
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Figure 16 illustrates another patient of interest, diagnosed with metastatic serous
carcinoma. After harvesting the ascites cells, we cultured them in tumorsphere forming
conditions as seen in the figure. RT-PCR data for this patient at both time points, asserts
expression of mRNA HERV-K type 1 and type 2 transcripts, ERV-3, and HERV-E41
transcripts . However, expression is clearly increased in all transcripts after tumorsphere
culture, except for ERV3 which decreased slightly. Finally, we wanted to determine if
HERV-K expression and other characteristics changed in response to this cancer stem cell
supporting environment. After staining with 6H5 mAb, anti-vimentin, anti-cytokeratin, antiNCL-L-5D3, anti-CD133, and anti-CD44, the results in Figure 17 show that the percentage
of positive populations for each marker increased after tumorsphere culture, except for
CD133 which decreased slightly.
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Figure 13: Human primary cell line characterization: HERV-K mRNA expression and cell
morphology in Patient #65 ascites and tumorspheres. Patient #65 was diagnosed with
metastatic adenocarcinoma. RT-PCR data for cells in culture 1 day post-harvest and 7 days
post-harvest in tumorsphere conditions. 2D images of cells in culture 1 day post-harvest
and 7 days post-harvest in tumorsphere conditions.
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Figure 14: Human primary cell line characterization: Quantitation of HERV-K cell surface
molecules in Patient #65 ascites. Patient #65 was diagnosed with metastatic
adenocarcinoma. Quantitation of HERV-K env molecules on the surface of primary cells
via QIFIKIT and FACS analysis. The gray, filled line represents the isotype control, the red
line represents the HERV-K positive population and the blue line represents a series of 6
bead populations coated with well-defined quantities of a mouse monoclonal antibody.
164,258 surface molecules of HERV-K were present on the surface of these cells.
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Figure 15: Human primary cell line characterization: Epithelial, mesenchymal, HERV-K+,
and stem cell populations in patient #65 ascites and tumorspheres via FACS. Patient #65
was diagnosed with metastatic adenocarcinoma. After patient tissue was harvested, cells
were gown in serum-free Epicult medium on 0.8% agarose coated plates to support
tumorsphere formation. Primary cells were characterized via staining 1 day post-harvest and
7 days post-harvest with 6H5 mAb (HERV-K expression), anti-vimentin Ab (mesenchymederived cells), anti-cytokeratin mAb (epithelial cells), anti-NCL-L-5D3 mAb (tumor
epithelial cells), anti-CD44 mAb (OC stem cells), and anti-CD133 mAb (OC stem cells),
followed by FACS analysis. A table at the bottom summarizes the FACS data.
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Figure 16: Human primary cell line characterization: HERV-K mRNA expression and cell
morphology in Patient #222 ascites and tumorspheres. Patient #222 was diagnosed with
serous carcinoma. RT-PCR data for cells in culture 1 day post-harvest and 7 days postharvest in tumorsphere conditions is shown. 2D images of the cells in culture 1 day postharvest and 7 days post-harvest in tumorsphere conditions is shown.
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Figure 17: Human primary cell line characterization: Epithelial, mesenchymal, HERV-K+,
and stem cell populations in Patient #222 ascites and tumorspheres via FACS. Patient #222
was diagnosed with serous carcinoma. Primary cells were characterized 1 day post-harvest
and 7 days post-harvest to determine differences. Primary cells were characterized via
staining with anti-vimentin Ab (mesenchyme-derived cells), anti-cytokeratin Ab (epithelial
cells), anti-NCL-L-5D3 Ab (tumor epithelial cells), anti-CD44 Ab (OC stem cells), antiHERV-K env protein (6H5) and anti-CD133 Ab (OC stem cells), and subsequent FACS
analysis depicted in the bottom panel. A table at the bottom summarizes the FACS data.
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3.5 Levels of anti-HERV-K Abs in OC, benign patient, and normal donor serum
samples
Our next objective was to determine if amounts of anti-HERV-K antibodies are
different between OC, benign patient, and normal donor serum samples. We obtained
several patients with various serum draws post operation. Therefore, “0m” indicated a
serum draw one day before the surgery and “6m” indicated a serum draw 6 months postsurgery. Human patient serum samples were diluted and added to ELISA plates coated
with purified HERV-K env protein. First we assayed 2 OC patients, #14 and #22, with two
blood draw dates and 4 patients with benign disease, #19, #16, #32, #34, and several
dilutions. As seen in Figure 18, titers of anti-HERV-K antibodies were significantly higher
in OC patients compared to patients with benign disease. Also in this graph, serum taken
the day before surgery (0m) was compared to serum taken 6 and 12 months post-surgery. No
trends were seen in antibody levels and further testing needs to be completed with longer
draw date span samples and in patients who experience tumor recurrence. A summary graph
in Figure 19 shows that anti-HERV-K antibody titers are significantly higher in patients with
OC (n=25) compared to patients with benign disease and normal donors (n=21). This data
confirms that anti-HERV-K antibodies present in patients at different stages of disease and
correlate with clinical and histological characteristics.
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Figure 18: ELISA assay with sera from OC and patients with benign disease. ELISA assay
was used to detect various titers of anti-HERV-K antibodies in OC patient and patients with
benign disease. Patient diagnoses are as follows: #14 = serous borderline, #22 = high grade
serous carcinoma, #19 = teratoma, #16 = teratoma, #32 = teratoma, #34 = teratoma. Human
sera was diluted and added to blocked ELISA plates coated with purified HERV-K protein.
0m indicates a serum draw days before the surgery to remove the tumor or benign disease
and 6m indicates a serum draw 6 months post-surgery. Significantly more anti-HERV-K
antibodies were found in OC patient sera compared to patients with benign disease.
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Figure 19: ELISA Summary: Detection of anti-HERV-K antibodies in serum from OC
patients, patients with benign disease, and normal donors. ELISA assay was used to detect
anti-HERV-K antibodies in OC patients, patients with benign disease, and normal donors.
Human sera was diluted and added to blocked ELISA plates coated with purified HERV-K
protein. Significantly more anti-HERV-K antibodies were found in OC patient sera (n=25)
compared to patients with benign disease and normal controls (n=21). A student’s t-test was
used to calculate significance.
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3.6 Characterization of lymphocytes obtained from OC and benign samples
Our encouraging results from the first aim served as a great precedent for our second
aim, to evaluate the immune responses triggered by HERV-K antigen in OC and benign
patients. Our first objective was to characterize the different types of lymphocytes present
in the PBMC and IVS samples. This is important because T cell infiltrates are frequently
associated with a favorable prognosis for many epithelial cancers 216, 264-272. Specifically, a
plethora of studies have documented infiltration by both CD4+ and CD8+ T cells in epithelial
OC. CD4+ helper T cells have no cytotoxic or phagocytic activity but instead activate other
immune cells. Examples of these activities include aiding in B cell antibody class
switching, activation and growth of cytotoxic CD8+ T cells, and bactericidal activity of
phagocytes. There are exceptions, including T-regs, natural killer cells and cytotoxic T cells
that express CD4, but these are not considered T helper cells. CD8+ cytotoxic T cells induce
death in tumor cells or cells that are infected with viruses or other pathogens. Studies have
shown that patients with ovarian tumors containing dense infiltrates of CD3+CD8+ T cells
experience unexpectedly favorable progression-free and overall survival 113, however the
association of tumor infiltrating lymphocytes subpopulations with clinical outcome remains
controversial 273 .
NK cells are widely known for their ability to kill cells infected by certain viruses,
intracellular bacteria and tumor cells. Also, their cytolytic activity and secretion of
cytokines and chemokines are crucial components of the innate immune system 274, 275. In a
recent study, autologous NK cells had the ability to recognize and kill human ovarian
carcinoma cells 276. Similarly, Alves PC, Andrade LA, Petta CA, Lorand-Metze I, Derchain
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SF, and Guimarães F demonstrated that effector cells enriched with CD56+ lymphocytes
were the main variable affecting target cell killing in patients with ovarian neoplasia 277.
As described in the Introduction, T-regs are a subpopulation of T lymphocytes that
down-regulate the immune response and accumulation of intratumoral T-regs was found to
be associated with a high mortality rate in OC patients146. Conversely, another group
determined that the presence of T-regs and activated CD4+ cells within the tumor
microenvironment was associated with improved overall progression-free survival in
patients with OC 273. In conclusion, it is the intricate balance between these effector cells
and regulatory T cells that is critical in determining patient outcome.
To classify the different populations, we stained cells with the following antibodies
and analyzed them by FACS: anti-CD4 to identify T helper cells, anti-CD8 to identify
CTLs, anti-CD25 to identify activated T and B cells, anti-CD56 to identify NK cells and
anti-FoxP3 to identify T-regs. Table 4 shows that upon transition from PBMC to IVS cell,
the percentage of T helper cells, CTLs, activated T and B cells, NK cells, and T-regs
increased in a patient diagnosed with benign disease, #182. A second patient diagnosed with
a benign cyst, #151, displayed an increase in the percentage of T helper cells, CTLs,
activated T and B cells, NK cells, but a slight decrease in T-regs. The remaining 2 OC
patients all displayed an increase in the percentage of T helper cells, CTLs, and activated T
and B cells, however a decrease in NK and T-reg positive cells.
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Table 4: Characterization of patient PBMCs and IVS cells: CD8+, CD4+, CD25+, CD56+,
and FoxP3+ populations via FACS. Cells were stained with anti-CD4 (T helper cells), antiCD8 (cytotoxic T cells), anti-CD25 (activated T and B cells), anti-CD56 (natural killer
cells), and anti-FoxP3(T-regs) antibodies and then analyzed on a BD FACS array. After
transition from PBMCs to IVS cells, populations of all specific cell types in both OC and
patients with benign disease either increased (green ↑) or decreased (red ↓).
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3.8 Changes in T cell proliferation in OC patients compared to samples from patients
with benign disease and normal donors
Our next goal was to focus on T-cell responses in ovarian patients. Many agents can
specifically or nonspecifically induce T cell activation resulting in proliferation of activated
T cells. In this work, we were interested in determining if HERV-K env protein could
specifically induce T cell proliferation. To accomplish this, we isolated PBMCs from patient
blood samples and generated IVS cells by combining PBMCs with autologous DCs pulsed
with HERV-K for 7 days. T cell proliferation specifically induced by DCs pulsed with
HERV-K env protein or KLH control protein were then compared between autologous
PBMC and IVS cells and between OC, patients with benign disease or normal donors via
[3H] thymidine incorporation assay. Figure 20 depicts 2 patients with benign disease and 1
with OC. T cell proliferation was clearly higher in the OC patient compared to the patients
with benign disease. Also, DCs pulsed with HERV-K induced greater T-cell proliferation
compared to DC pulsed with KLH, unpulsed DCs, or media alone. Another T cell
proliferation assay is depicted in Figure 21 showing results for 4 patients with OC, one with
benign disease and 3 normal donors. T cell proliferation was higher in OC patients
compared to the patient with benign disease and the normal donors. DCs pulsed with
HERV-K induced greater T cell proliferation compared to DCs pulsed with KLH, unpulsed
DCs, or media alone. Finally, DCs pulsed with HERV-K induced greater T-cell proliferation
in IVS cells than in PBMCs.
Figure 22 illustrates a T cell proliferation summary including OC patients (n=8) and
patients with benign disease or normal donors (n=6). Overall, HERV-K antigen induced
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significantly greater T cell proliferation in IVS cells in OC patients compared to the control
protein. HERV-K antigen also induced significantly greater T cell proliferation of IVS cells
in OC patients than in benign disease patients and normal controls.
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Figure 20: T cell proliferation assay. IVS cells were combined with DCs pulsed with
HERV-K protein or with KLH control protein. Cells were also combined with media alone
and unpulsed DCs as negative controls. T cell proliferation is clearly greater in patients with
OC compared to benign diseases when IVS cells are combined with HERV-K pulsed DCs.

84

C.P.M

15000

Media
DC
DC+KcRNA
DC+E6cRNA

10000

5000

S
IV

M
C

S

ND2

PB

IV

M
C

S

ND1

PB

IV

M
C

S

#15

#14

PB

IV

S

M
C
PB

IV

M
C

S

#7

PB

IV

M
C

S

#8

PB

IV

PB

M
C

0

ND3

Patient

Figure 21: T cell proliferation assay. Patient diagnoses are as follows: #8=benign simple
cyst, #7=metastatic adenocarcinoma, #14=serous borderline, #15=serous borderline, ND13=normal female donors. PBMCs or IVS cells were combined with DCs pulsed with cRNA
for the HERV-K protein or cRNA for E6 control protein. T cell proliferation is clearly
greater in patients with OC compared to benign diseases when IVS cells are combined with
HERV-K cRNA pulsed DCs.
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Figure 22: T cell proliferation summary. IVS cells were combined with DCs pulsed with
HERV-K protein or with KLH control protein. T cell proliferation is significantly greater in
patients with OC (n=8) compared to benign diseases or normal donors (n=6) when IVS cells
are combined with HERV-K pulsed DCs. T cell proliferation is significantly greater when
OC patient IVS cells are combined with HERV-K pulsed DCs as compared to KLH pulsed
DCs. ). A student’s t-test was used to calculate significance. b=benign or normal, t=tumor.
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3.9 Changes in IFN-γ secretion in OC patients compared to samples from patients with
benign disease and normal donors
IFN-γ is secreted by activated CD4+ and CD8+ cells and is critical for innate and
adaptive immunity and for tumor control. Therefore, we utilized an ELISPOT assay to
analyze IFN–γ production at the single cell level. In this particular assay, a spot forms at
the site where secreted cytokine is bound; therefore, one spot is equal to one molecule
secreting cell. The microplate is then subjected to an automated ELISPOT reader to
determine the amount of spots per well. This allows the frequency of cells secreting IFN–γ
to be calculated. To begin this assay, we isolated PBMCs from patient blood samples and
generated IVS cells by combining PBMCs with autologous DCs pulsed with HERV-K for 7
days. 1x105 KSU IVS cells or PBMCs were combined with media, 5x103 autologous DCs,
5x103 DCs pulsed with HERV-K protein or 5x103 DC pulsed with KLH protein, and
incubated for 16 hours before adding the color substrate. IFN–γ production, specific to
HERV-K env protein pulsed DCs, used as antigen presenting cells, was then compared
between PBMC and IVS cells obtained from the same donors. IFN–γ production was also
compared between OC patients, patients with benign disease, and normal donors.
Figure 23 illustrates an IFN–γ ELISPOT assay with 1 OC patient, diagnosed with
adenocarcinoma, and 3 normal donors. The image at the top is the actual ELISPOT plate,
and the column graph below quantifies the number of spots for this plate. Clearly more
IFN-γ secretion is observed when IVS cells from the OC patient are combined with HERVK pulsed DCs, compared to all 3 normal donors. Also, there is clearly less IFN-γ secretion
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when IVS or PBMCs are combined with media alone, unpulsed DCs, or DCs pulsed with
KLH protein, as compared to HERV-K pulsed DCs.
There has been great interest in the expression of retroviral transmembrane proteins
in human diseases. As discussed previously in the Introduction, the env genes encode a
surface (SU) protein and a transmembrane (TM) protein. The function of the TM protein is
to hold the SU domain in the viral envelope and it aids in membrane fusion.
Transmembrane envelope proteins of different retroviruses have been correlated with
immunosuppressive properties 278, 279. After demonstrating the strong expression of HERVK in melanomas 76, it was established that there was cell surface expression of the TM
envelope protein in melanomas and melanoma cell lines, and this protein may interact with
the neighboring lymphocytes and induce immunosuppression. Alternatively, in our lab, we
discerned a positive correlation between anti-HERV-K TM serum reactivity and tumor
progression in human BC samples. We also discovered that the HERV-K TM envelope
protein is capable of triggering strong humoral immune responses. Figure 24 illustrates
another IFN-γ ELISPOT assay including 1 normal donor and 1 OC patient whose
lymphocytes were obtained 1 days before surgery (0 month) and again sampled 6 months
after the tumor was removed. We additionally combined IVS or PBMCs with DCs pulsed
with the TM protein. IFN-γ production is clearly seen when the OC patient IVS sample is
combined with HERV-K TM and HERV-K pulsed DC cells. There was no IFN-γ production
seen with PBMC cells or in the normal donor. This data further substantiates our previous
data that TM is not immunosuppressive.
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Figure 25 display a summary of IFN-γ ELISPOT assays including OC patients (n=9)
and patients with benign disease or normal donors (n=6). We concluded that significantly
more IVS cells from OC patients secrete IFN-γ than PBMCs from OC patients when
stimulated with DCs pulsed with KSU protein. Also, significantly more IVS cells from OC
patients secrete IFN-γ when combined with KSU than with control protein. Finally,
significantly more IVS cells from OC patients secrete IFN-γ than IVS cells from benign
disease patients and normal donors.
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Figure 23: IFN-γ ELISPOT assay. Patient #103 was diagnosed with adenocarcinoma.
ND59, ND10, and ND11 represent normal female donors. An image of an ELISPOT plate is
displayed at the top. KSU IVS or PBMC were combined with DCs pulsed with HERV-K
protein, DCs pulsed with KLH control protein, media alone, or unpulsed DCs. A purple spot
represents one molecule secreting cell. Spots are clearly seen when IVS cells are combined
with HERV-K pulsed DCs but not media, unpulsed DCs, or DCs pulsed with control protein
in the OC patient. Considerably less or no spots are seen in the normal donors. A column
graph representing the number of spots in each patient from the same ELISPOT plate is
displayed at the bottom.
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Figure 24: IFN-γ ELISPOT: Patient #153 was diagnosed with high grade papillary serous
carcinoma and BC. ND11 represents a normal female donor. KSU IVS or PBMC were
combined with DCs pulsed with HERVK protein, DCs pulsed with KLH control protein,
DCs pulsed with TM protein media alone, or unpulsed DCs. A purple spot represents one
molecule secreting cell. Spots are clearly seen when IVS cells are combined with HERV-K
pulsed DCs but not media, unpulsed DCs, or DCs pulsed with control protein in the OC
patient. Considerably less or no spots are seen in the normal donors. 0 and 6 months
indicate lab blood draw dates post operation.
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Figure 25: Summary for ELISPOT. OC patients (n=9) are compared with patients with
benign disease or normal donors (n=6). KSU IVS or PBMC were combined with 5x103 DCs
pulsed with HERV-K protein, DCs pulsed with KLH control protein, unpulsed DCs, or
media alone. Significantly more spots are seen when IVS cells are combined with HERV-K
pulsed DCs compared to IVS cells combined with KLH pulsed IVS cells in OC patients.
Significantly more spots are seen when IVS cells are combined with HERV-K pulsed DCs in
OC patients compared to patients with benign disease. Significantly more spots are seen
when IVS cells are combined with HERV-K pulsed DCs in OC patients compared to
PBMCs in OC patients. A student’s t-test was used to calculate significance.
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3.10 CTL activity using autologous OC and benign patient primary target cells
Our paramount objective was to determine the ability of antigen specific T cells to
kill autologous target cells expressing HERV-K. We wanted to ensure that these antigenspecific T cells kill only cancer cells which express HERV-K but not benign or normal cells
that do not express HERV-K. We also wanted to ensure that T cells could kill target cells
from the same patient instead of an established cancer line not specific to the patient. The
standard CTL assay indicates the presence and cytotoxic activity of T cells to a specific
antigen. Target cells, primary tumor or benign cells or adjacent uninvolved cells isolated
from patient tissue, are labeled with 51Chromium and combined with IVS cells isolated from
autologous patient blood samples.
Figure 26 presents a CTL assay including both tumor and adjacent uninvolved cells
obtained from an OC patient diagnosed with malignant mixed mullerian tumor. The results
show that IVS cells from the OC patient exhibited higher specific lysis of tumor target cells
compared to adjacent uninvolved cells. Also, specific lysis was higher when target cells
were pulsed with HERV-K compared to E6 or unpulsed. Figure 27 presents a CTL assay
including both tumor and adjacent uninvolved cells obtained from an OC patient diagnosed
with mullerian borderline tumor with isolated foci of invasion. The results show that IVS
cells from the OC patient exhibited higher specific lysis of tumor target cells compared to
adjacent uninvolved cells. Also, specific lysis was higher when target cells were pulsed with
HERV-K compared to unpulsed. Specific lysis was also high when target cells were pulsed
with E6 protein. This possibly indicates that this female is HPV positive.
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Figure 26: CTL assay using human patient autologous cells as target cells: Patient #115
was diagnosed with malignant mixed mullerian tumor and both tumor and adjacent
uninvolved tissue was harvested. CTL assays were performed using a standard 4-hour 51Crrelease assay. Autologous primary OC tumor and adjacent uninvolved cells lines were
pulsed with HERV-K or KLH control protein and used as target cells. Cells were plated at
effector to target cell ratios of 100:1, 50:1, 25:1, and 12.5:1. Specific lysis is highest when
autologous target cells expressing HERV-K compared to E6 protein are combined with IVS
cells from this patient. % specific lysis is considerably higher when IVS cells are combined
with autologous tumors cells compared to adjacent uninvolved cells.
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Figure 27: CTL Assay. #105 was diagnosed with mullerian borderline tumor with isolated
foci of invasion. CTL assays were performed using a standard 4-hour 51Cr-release assay.
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERVK or E6 control protein and used as target cells. Cells were plated at effector to target cell
ratios of 100:1, 50:1, 25:1, and 12.5:1. Specific lysis is highest when autologous target cells
expressing HERV-K compared to E6 protein are combined with IVS cells from this patient.
% specific lysis is considerably higher when IVS cells are combined with autologous tumors
cells compared to adjacent uninvolved cells.
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3.11 Effects of T-reg depletion on CTL activity using autologous OC, adjacent
uninvolved, and benign patient primary target cells
T-regs within the tumor microenvironment are a crucial component of the tumor
immunosuppressive network. Therefore, our final objective was to deplete T-regs from our
lymphocyte population and determine the effect on specific lysis of HERV-K expressing
target cells. We utilized a CD4+CD25+CD127dim/– regulatory T cell isolation kit in order to
magnetically isolate T-regs from our populations. Our lymphocytes fell into three groups:
“T-reg-” indicated a lymphocyte population depleted of T-regs, “T-reg+” indicated a
lymphocyte population consisting of isolated T-regs, and “both” indicated a lymphocyte
population not subjected to the isolation kit. CTL assays were then conducted as described
in the Material and Methods section.
Figure 28 includes CTL data from 2 OC patients diagnosed with adenocarcinoma
and 2 patients diagnosed with benign disease. IVS cells from each patient were
magnetically separated into T-reg populations as described above, and used as effector cells.
The results show that overall specific lysis was higher in the OC patients compared to
patients with benign disease. Specifically, T-reg depletion resulted in increased specific
lysis of OC target tumor cells pulsed with HERV-K in #103. Figure 29 displays data from
one OC patient. Overall, specific lysis was higher in the OC target cells compared to
adjacent uninvolved cells. Also, OC target cells pulsed with HERV-K showed higher
specific lysis than the unpulsed target cells. T-reg depletion did not exhibit a cytolytic
advantage in this patient.
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Figure 30 displays CTL data from 2 OC patients and 2 patients with benign disease.
The results show that overall specific lysis was higher in the OC patients compared to
patients with benign disease. Also, both OC patients benefited from T-reg depletion,
manifesting in greater specific lysis of target cells expressing HERV-K. Figures 31 and 32
both include CTL data from 1 OC patient and 1 patient with benign disease. Specific lysis is
clearly greater when target cells from the OC patient are pulsed with HERV-K compared to
the patient with benign disease. T-reg depletion benefited the OC patients but not the
patients with benign disease. Figure 33 includes CTL data from 1 OC patient and 1 patient
with a teratoma. Specific lysis is clearly greater when target cells from the OC patient are
pulsed with HERV-K compared to the patient with a teratoma. T-reg depletion did not
benefit these patients. Finally, Figures 34 and 35 both include CTL data from 1 OC patient.
Specific lysis was greater in both patients when target cells where pulsed with HERV-K
compared to KLH control protein. T-reg depletion benefited 1 OC patient of the two.
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Figure 28: CTL Assay: Human patient autologous cells as target cells. Primary human
tissue was harvested from patients with various diagnoses. CTL assays were performed
using a standard 4-hour 51Cr-release assay. Autologous primary OC tumor and benign cells
were pulsed with HERV-K and used as target cells. Effector cells were separated into Treg-, Treg+ and unseparated groups. Cells were plated at effector to target cell ratios of
100:1, 50:1, 25:1, and 12.5:1. Specific lysis is highest when autologous cells expressing
HERV-K are combined with IVS cells from OC patients compared to patients with benign
disease.
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Figure 29: CTL Assy. #112 was diagnosed with serous borderline carcinoma/mucinous
borderline adenocarcinoma. CTL assays were performed using a standard 4-hour 51Crrelease assay. Autologous primary OC tumor and adjacent uninvolved cells lines were
pulsed with HERV-K and used as target cells. Cells were plated at effector to target cell
ratios of 100:1, 50:1, 25:1, and 12.5:1. Specific lysis is highest when autologous target cells
expressing HERV-K are combined with IVS cells from this patient.
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Figure 30: CTL assay. CTL assays were performed using a standard 4-hour 51Cr-release
assay. Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with
HERV-K and used as target cells. Cells were plated at effector to target cell ratios of 100:1,
50:1, 25:1, and 12.5:1. Specific lysis is highest when autologous cells expressing HERV-K
are combined with IVS cells from OC patients compared to patients with benign disease.
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Figure 31: CTL Assay. CTL assays were performed using a standard 4-hour 51Cr-release
assay. Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with
HERV-K and used as target cells. Cells were plated at effector to target cell ratios of 100:1,
50:1, 25:1, and 12.5:1. Specific lysis is highest when autologous cells expressing HERV-K
are combined with IVS cells from OC patients compared to patients with benign disease.
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Figure 32: CTL assays were performed using a standard 4-hour 51Cr-release assay.
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERVK and used as target cells. Cells were plated at effector to target cell ratios of 100:1, 50:1,
25:1, and 12.5:1. Specific lysis is highest when autologous cells expressing HERV-K are
combined with IVS cells from OC patients compared to patients with benign disease.
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Figure 33: CTL assays were performed using a standard 4-hour 51Cr-release assay.
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERVK and used as target cells. Cells were plated at effector to target cell ratios of 100:1, 50:1,
25:1, and 12.5:1. Specific lysis is highest when autologous cells expressing HERV-K are
combined with IVS cells from OC patients compared to patients with benign disease.
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Figure 34: CTL assays were performed using a standard 4-hour 51Cr-release assay.
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERVK and used as target cells. Cells were plated at effector to target cell ratios of 100:1, 50:1,
25:1, and 12.5:1. Specific lysis is highest when autologous target cells expressing HERV-K
compared to KLH protein are combined with IVS cells from this patient.
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Figure 35: CTL assays were performed using a standard 4-hour 51Cr-release assay.
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERVK and used as target cells. Cells were plated at effector to target cell ratios of 100:1, 50:1,
25:1, and 12.5:1. Specific lysis is highest when autologous target cells expressing HERV-K
compared to KLH protein, are combined with IVS cells from this patient.
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Figure 36 displays a CTL assay summary including OC samples (n=28), adjacent
uninvolved samples (n=10), and benign samples (n=18). Overall, cytolytic activity was
significantly greater when IVS effector cells were combined with autologous tumor target
cells than with autologous uninvolved target cells. Cytolytic activity was significantly
greater when IVS effector cells were combined with autologous tumor target cells than with
autologous benign target cells. Cytolytic activity was significantly greater when T-regeffector cells were combined with autologous tumor target cells than with autologous
adjacent uninvolved target cells. Cytolytic activity was significantly greater when T-regeffector cells were combined with autologous tumor target cells than with autologous benign
cells. Finally, T-reg depletion led to higher specific lysis of autologous tumor and benign
target cells. Of the 22 OC patients tested, 14 (64%) displayed higher specific lysis of tumor
target cells after T-reg depletion.
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Figure 36: CTL Assay Summary. Target cells pulsed with KSU and an effector to target ratio of 50

to 1. Human patient autologous cells were used as target cells. Primary human tissue was
harvested from OC patients (n=28), uninvolved normal tissue (n=10) and patients with
benign disease (n=18). CTL assays were performed using a standard 4-hour 51Cr-release
assay. Primary OC tumor and benign cells were pulsed with HERV-K and used as target
cells. Cytolytic activity was significantly greater when IVS effector cells were combined
with autologous tumor target cells than with autologous uninvolved target cells. Cytolytic
activity was significantly greater when IVS effector cells were combined with autologous
tumor target cells than with autologous benign target cells. Cytolytic activity was
significantly greater when T-reg effector cells were combined with autologous tumor target
cells than with autologous adjacent uninvolved target cells. Cytolytic activity was
significantly greater when T-reg effector cells were combined with autologous tumor target
cells than with autologous benign cells. T-reg depletion led to higher specific lysis of
autologous tumor and benign target cells. A student’s t-test was used to calculate
significance between groups.
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Chapter 4: Discussion
Approximately 8.3% of the human genome is derived from HERVs, resulting from
integration events that took place millions of years ago. Most HERVs are defective and
unable to produce infectious particles; however, some of them have retained the capacity to
encode viral proteins 280. HERV-K is the only family that has maintained intact ORFs for
gag, pro, pol, and env. As discussed previously, HERV genes play important roles in some
normal physiological events but unfortunately have been associated with several
autoimmune diseases and cancer. The expression of HERV-K mRNA and protein and
production of retroviral particles has been detected in human cancer (Table 1). The primary
focus in our laboratory has been on HERV-K expression in BC patients 94-96. However, in
2006, our group was the first to report that HERV-K env protein is also expressed on the
surface and in the cytoplasm of OC cells. We also determined that expression of HERV-K
env mRNA was greater in ovarian epithelial tumors than in normal ovarian tissues. Finally,
we discovered anti-HERV antibodies in patients with OC, but not in normal female
controls175. In this study, we confirm and augment our previous findings by providing
cogent data on HERV-K expression and the immune responses they trigger in a new cohort
of patient samples.
In this study, we amassed blood and tissue samples from patients with OC and patients
with benign disease. Within this new patient cohort, several patients provided both OC and
adjacent uninvolved samples, which were invaluable in determining differences in HERV-K
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expression within one patient. Blood samples from normal female donors were also
collected and compared.
Our first objective was to determine the expression of HERV-K at the transcriptional
level in our samples. Our results show that patients with OC had overall stronger expression
of HERV-K transcripts compared to patients with benign disease and adjacent uninvolved
samples. We had the ability to compare OC and adjacent uninvolved samples, as well as
OC and benign samples from the same patient. In every patient pair, HERK-K expression
was greater in OC than in adjacent uninvolved and benign samples. Our next objective was
to determine if HERV-K expression at the translational level showed similar results. We
implemented IHC, IFS, FACS and dry cell ELISA to achieve this. Biopsies from patients
(n=406) with OC, benign disease and normal epithelium biopsies were assayed. HERV-K
expression was detected in endometrioid adenocarcinoma and serous adenocarcinoma
samples but not in benign cysts or normal epithelium. IFS data from DOV13, an
established OC cell line, indicates both surface and cytoplasmic expression of HERV-K
which substantiates data from our 2006 paper. IFS analysis shows that human primary cells
lines, distinctly exhibit greater cell surface expression of HERV-K in OC samples compared
to benign samples (Figure 8, 10, 11)
Of great importance was the characterization of our primary human cell lines harvested
from OC and benign samples. As mentioned previously, it has been determined that
epithelial and mesenchymal cells undergo dramatic changes in their cytoskeletal scaffolds
during tumorigenesis that are sometimes unpredictable. These observations may be due to
the fact that tumors have the potential to initiate expression of a novel IF, or alternatively,

109

may cease to express a normally present IF 281. This infidelity of IF expression has been
observed in vitro in specific tumor cell lines of human malignancies and includes expression
of vimentin by epithelial cells, expression of cytokeratin by mesenchymal cells, or
coexpression of both 251, 262, 263, 281-285. Indeed Hendrix and his colleagues determined that
cytokeratin and vimentin positive human BC cells displayed increased invasive potential,
proliferation rates, clonogenicity, and tumorigenicity compared to cells in which vimentin
and cytokeratin was transiently down-regulated 263. In one study, six permanent human
tumor cell lines established from patients with serous adenocarcinomas of the ovary showed
co-expression of cytokeratins (7, 8, 17, 18, and 19) and vimentin 286. In another study,
Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, and Hendrix
MJ determined that tumor cells which expressed both cytokeratin and vimentin in
approximately equal ratios, translated to poorer survival of these BC patients 254. To add
more complexity to this subject, in one study, epithelial cells in most benign breast disease
samples tested were positive for cytokeratin 8 and 18 287. Another study showed that coexpression of cytokeratin and vimentin was found in all benign prostatic epithelium and in
83% of adenocarcinomas 288.
In our study, we indeed observed that the majority of OC human primary cells lines
positively coexpressed vimentin and cytokeratin. Co-expression was also observed in the
benign primary cells. Another group illustrated that loss of cytokeratin 8 and 18 expression
and concurrent up-regulation of vimentin suggested that disseminated BC tumor cells had
acquired a mesenchymal-like, aggressive phenotype 247. Contrary to this, the majority our
OC and benign primary cells positively expressed cytokeratin 8 and 18. IFS data displayed

110

the morphological appearance of these vimentin and cytokeratin expressing cells as
interwoven IF fibers (Table 2 and Figure 8).
In order to understand this up-regulation of vimentin in our primary patient cells, we
should observe normal epithelial behavior. In normal wound healing, epithelial cells
undergo an epithelial-mesenchymal transition (EMT) whereby their phenotype changes to a
fibroblastic appearance, enabling them to move into the wound site, after which they
reconstruct the epithelium by reverting back to an epithelial state via mesenchymalepithelial transition (MET). However, in epithelial carcinomas, cells do not revert back
from the EMT, and take on an aggressive, invasive role 248.
Based on their resistance to traditional cancer therapies and presumed ability to
recapitulate the original tumor, cancer stem cells are believed to be the source of recurrent
OC 228. There is growing evidence that tumor initiating cells capable of forming new tumors
are rare and the majority of cancer cells are nontumorigenic 289. The notion that cancer is
driven by tumor initiating cells has obvious therapeutic implications but curative therapy
should be designed to target these initiating cells instead of the bulk of nontumorigenic cells
290

. Therefore, our next objective was to characterize OC stem cell populations in two

previously described individual patients. Patient #65 was diagnosed with metastatic
adenocarcinoma, and the tumor cells from this patient had an epithelial morphology. Cells
were harvested on day 1 and then grown in tumorsphere inducing conditions for 6 days.
RT-PCR confirmed that transcripts for HERV-K Type1 and Type 2, ERV-3, and HERVE41 increased upon tumorsphere formation. QIFIKIT and FACS assay confirmed the
presence of HERV-K surface expression. FACS confirmed populations for mesenchyme,
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epithelial, HERV-K+, and tumor epithelial cells also increased upon tumorsphere formation.
We also included two antibodies for CD133 and CD44, OC stem cell markers, and
determined that populations of CD44+ cells increased upon tumorsphere formation. The
increased expression of HERV-K and CD44 populations indicates that targeting HERV-K in
OC cells could possibly be beneficial in eradicating stem cell populations (Figure 15).
The second patient characterized was diagnosed with serous carcinoma which had
metastasized and formed an ascites. One day post-harvest, cells took on an epithelial–like
morphology in culture. In a recent study, ascites from a patient diagnosed with advanced
ovarian adenocarcinoma grew in an anchorage-independent manner in vitro as spheroids and
presented the distinctive phenotype of CD44+cKit+, expressed both epithelial and
mesenchymal markers and established tumors that were histopathologically similar to those
in the human disease 291. Therefore to promote an anchorage-independent, self-renewing
sphere population, we plated ascites cells in serum-free Epicult media on 0.8% agarose
coated plates for 7 days 240. To investigate the phenotypic characteristics of these
tumorsphere cells, FACS was used to analyze the expression of common OC stem cell
markers. Indeed, after tumorsphere culture, expression of epithelial, tumor epithelial and
mesenchymal markers, as well as the cancer stem cell marker CD44 increased, as was also
observed 291. CD133 expression decreased slightly Figure 17. The most valuable
observation was the concomitant increase HERV-K as the most alluring potential vaccine
targets are molecules that are associated with cancer stem cells and/or the EMT process 165.
The similarities between cells undergoing EMT and the acquisition of “stem-like”
characteristics have been explored by recent studies 292.
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Moving our focus to immune responses generated by HERV-K, we next compared the
levels of anti-HERV-K antibodies in serum from OC patients to patients with benign
disease. Our results show a positive correlation between anti-HERV-K serum reactivity and
tumor progression. In an attempt to discern a pattern in anti-HERV-K antibody levels
during post-operative spans, the data produced was inconclusive. Our patient sample cohort
is limited in terms of samples available during remission, and recurrence and further studies
will be necessary once additional samples become available (Figure 18-19).
After identifying a humoral response against HERV-K in OC patients, our next
objective was to explore HERV-K-specific T-cell responses. To accomplish this, it was
very important to first characterize our patient PBMC and IVS populations. This is critical
because T cell infiltrates are frequently associated with a favorable prognosis for many
epithelial cancers 216, 264-272. However, it is the intricate balance between these effector cells
and regulatory T cells that determine the critical outcome of the patient. Although changes in
cell populations were not significant, trends were observed. In the patient diagnosed with
benign disease, the positive populations of T helper cells, cytotoxic T cells, activated T and
B cells, NK cells, and T-regs increased upon conversion from PBMCs to IVS cells. A second
patient diagnosed with benign disease displayed the same trends except a slight decrease in
T-regs. In the patients diagnosed with OC, the positive populations of T helper cells,
cytotoxic T cells, activated T and B cells increased while positive populations of NK cells
and T-regs decreased. These increases in particular effector cell populations are what
triggered the strong cell-based immune reactions against HERV-K expressing cells in our
subsequent assays discussed below. A decrease in T-regs initially appears beneficial but this
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is hard to discern because the exact balance between effector cells and T-regs is unknown
(Table 4).
A profound biological issue in limiting the efficacy of cancer vaccines is the
limitation on the ability of T cells to expand in number in response to antigenic stimulation.
Normally, strict biological limits imposed on the immune system to prevent excessive T-cell
activation and expansion 293. Therefore, our subsequent goal was to determine if HERV-K
could induce T cell activation resulting in proliferation of activated T cells. Our results
show that T cell proliferation was significantly greater when OC patient IVS cells are
combined with HERV-K pulsed DC, compared to KLH pulsed DCs. T cell proliferation is
also higher when HERV-K pulsed DCs are combined with IVS from OC patients, compared
to patients with benign disease (Figures20-23). IFN-γ is secreted by activated CD4+ and
CD8+ cells, so we next employed an ELISPOT assay, which is a common assay used to
monitor T cell immune responses. Results show that there are significantly more IFN-γsecreting effector cells when IVS cells are combined with HERV-K pulsed DCs, compared
to IVS cells combined with KLH pulsed IVS cells in OC patients. Significantly more IFNγ-secreting effector cells are seen when IVS cells are combined with HERV-K pulsed DCs in
OC patients compared to patients with benign disease. Finally, significantly more IFN-γsecreting effector cells are present when IVS cell are combined with HERV-K pulsed DC in
OC patients compared to PBMCs in OC patients (Figure 23-25). These results are akin to
the results seen in our BC patient samples 94. These results are also parallel to results
published by Mullins CS and Linnebacher M who discovered that stimulation of T
peripheral T cells with autologous DCs pulsed with HERV-H retroviral peptides resulted in
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sustained proliferation of predominantly CD8+ T cells and high numbers of IFN-γ secreting
T cells 294.
IFN-γ production and proliferation are clear signs of specific activation, however
they do not prove cytotoxic ability. CD8+ cytotoxic T lymphocytes are extremely important
effector cells of the immune system and destroy cells that express foreign antigens on their
surface. Thus, our most powerful results are seen in our CTL assays utilizing patient
lymphocytes and autologous target cells. Cytolytic activity was significantly greater when
IVS effector cells were combined with autologous tumor target cells than with autologous
uninvolved target cells. Cytolytic activity was also significantly greater when IVS effector
cells were combined with autologous tumor target cells compared to autologous benign cell
(Figure 26-27). Overcoming suppressive mechanisms found within the tumor
microenvironment in order to enhance efficacy is a major challenge for current approaches
to cancer vaccination. Therefore our next goal was to determine the effects of T-reg
depletion on cytolytic activity. We discovered that cytolytic activity was significantly
greater when T-reg effector cells were combined with autologous tumor target cells than
with autologous adjacent uninvolved target cells. Also, cytolytic activity was significantly
greater when T-reg effector cells were combined with autologous tumor target cells than
with autologous benign cells. Overall, of all the OC patients tested, 64% displayed higher
specific lysis of tumor target cells after T-reg depletion (Figure 28-35). Therefore, future
vaccine regimens with HERV-K have the potential of an increase in efficacy upon
combination with T-reg depletion methods. This is the first report to explore the immune
responses triggered by HERV-K in OC patients and these results are a beneficial
contribution supporting optimism for the future of OC immunotherapeutics.
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Chapter 5: Conclusion and Future Studies

5.1 Conclusion
The history of cancer immunotherapy began in 1891 when William Coley, a
surgeon, injected live or inactivated Streptococcus pyogens and Serratia marcescens into the
tumors of patients in order to reproduce remissions of sarcomas observed in patients with
erysipelas 295. The injected toxins were used to stimulate antibacterial phagocytes that might
kill bystander tumor cells. However, this approach was never embraced by oncologists
because of the many risks associated with the administration of infectious agents 215.
Significant responses in cancer immunology occurred over the following 40 years; however,
successes were sporadic. Today, cancer immunotherapy is coming of age with the advent of
inhibitors that target oncogenic pathways, agents that prime and guide a patient’s immune
response, and pharmacodynamics biomarkers to identify efficacy of a particular treatment
215

.
There are many impediments to success in the cancer vaccine realm. First,

expression of the tumor antigen in the target tumor population may be inadequate for
predicting the ability to generate effective T-cell responses. In addition, the antigen
expression within the tumor bed can be heterogeneous and the relative specificity of a
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tumor-associated antigen may be the same for tumor versus normal adult tissue. However,
in our study, we found increased expression of HERV-K in OC samples compared to normal
control or benign disease samples and evidence that HERV-K indeed generates strong T-cell
responses. Secondly, the optimal adjuvant for producing antitumor CD8+ T-cell responses
that can be used safely and effectively in humans is not yet clear 215. Finally, the
effectiveness of a tumor-specific T-cell population may be limited by the multiple
mechanisms of immunosuppression used by tumors to protect them from T-cells. However,
in our study, we found that T-reg depletion resulted in higher specific lysis levels for target
cells expressing HERV-K. The development of tumor immunotherapies is an extremely
active field and characterization of novel tumor-associated antigens is essential because they
minimize the risk of autoimmunity. A novel tumor associated antigen has several
requirements. First, it is expressed in a significant proportion of patients with a particular
cancer type. Secondly, it is not expressed or expressed at low levels in normal tissues.
Thirdly, it is immunogenic
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. Our data demonstrates that HERV-K is indeed a novel

tumor-associated antigen that elicits a strong immune response due to its inherent viral
quality, making it a strong potential as an OC vaccine. We have efficaciously asserted that
impediments to a successful cancer vaccine can be overcome and we look forward with
unequivocal optimism in this new era of cancer immunotherapy.

5.2 Future Studies
The field of therapeutic cancer vaccines has reached several new and significant
milestones in scientific empiricism. Great strides have been made in vaccine-delivery
systems for the induction and enhancement of host antitumor immune responses.
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Immunostimulants have been shown enhance immunogenic properties of vaccine
preparations. Finally, the development and characterization of tumor-associated antigens
overexpressed only in tumor cells and not normal cells has increased the efficacy and
decreased the toxicity of vaccines. There are numerous types of vaccines that have been
explored in preclinical and clinical trials, and some are currently being evaluated in the
clinic. We feel it advantageous to detect successes in these current vaccines and apply or
combine them with HERV-K in future studies.
Whole tumor vaccines are advantageous because numerous tumor associated
antigens and tumor-specific antigens are present. These tumor cells can either be obtained
for the same patient or from other patients. Disadvantages include high costs associated
with custom vaccine production and considerable variability of tumors among patients 296301

. Additionally, allogenic vaccines produce alloimmunity to nontumor components,

altering the immune response. Another vaccine approach involves direct injection of
cytokine genes or costimulatory molecule genes into the tumor. B7-1, a T cell costimulatory
molecule on the surface of antigen-presenting cells, interacts with CD28 for up-regulation of
T cell function and cytotoxic T lymphocyte-associated antigen (CTLA-4) for downregulation of T cell function. Addition of B7-1 to an immunogenic tumor has been shown to
make the tumor more immunogenic in preclinical studies 302. Similar results are seen when
intercellular adhesion molecule (ICAM)-1 and lymphocyte function-associated antigen
(LFA)-3 have been added to tumors with marked success. The advantage of this approach is
that the vaccine contains unique tumor-associated antigens and tumor-specific antigens
specific to the patient. Indeed, clinical studies have shown that recombinant vectors
expressing the B7-1 costimulatory molecule have been directly injected into melanoma and
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carcinoma lesions 303. Another clinical study utilizing recombinant vectors containing B7-1,
ICAM-1 and LFA-3 injected directly into melanoma tumors has exhibited positive results
304

. Recombinant vectors containing cytokines can also be used and have been administered

in preclinical models 305, 306 and in prostate tumors clinically 307. Vectors expressing GMCSF have also been administered in melanoma patients 308.
Successes have also been shown with administration of peptide-based vaccines
because peptides do not contain parts of the molecule shared with normal cellular proteins as
compared to whole proteins. Peptides are inexpensive, easy to prepare, and minimize the
potential for autoimmunity. On the other hand, the inherent specificity of peptides could
lead to activation of only CD8+ cells inducing a response that is short-lived due to the
absence of CD4+ cells. Also, peptides are beneficial only in patients who have a specific
HLA allele. Numerous clinical trials are currently testing peptide vaccines including HPV
309

, ras 310, 311, HER-2/neu 312, MAGE 313, MART-1, tyrosinase 314, gp100 315, 316, CEA 317,

MUC-1 318, and PSMA 319, 320.
Vectors as a means of vaccine delivery have also been explored 321-327. Vector based
vaccines are advantageous because of the flexibility of inserting the entire tumor antigen,
just parts of the gene, or multiple genes. Indeed several clinical trials with recombinant
vaccinia, a vaccine vector from the poxvirus group, containing tumor-associated antigens
such as CEA 328, MUC-1, PSA 329, and HPV 315, 330, have been completed and others are
ongoing 331-333. Unfortunately, there is the possibility of development of host-induced
immunity to the vector itself, limiting continued use. Plasmid DNA vectors are another
vaccine-delivery system used in studies however, how these vectors induce an immune
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response is not fully understood 334. Current clinical trials employing this technique include
DNA vaccines encoding melanoma antigens such as MART-1 335, gp100 336, and PSA 337.
DC vaccines have created great excitement in the cancer vaccine field because they
are the most potent antigen presenting cell 338, 339. This method involves loading the DC
with a peptide, protein, anti-idiotype Ab, apoptotic bodies from tumor cells or actually
fusing it with a tumor cell 340-343. Unfortunately, DC vaccines are extremely expensive and
require great effort in isolating and culturing large amounts of PBMCs from each patient.
In April 2010, the Food and Drug Administration (FDA) approved Provenge
(sipuleucel-T), the first active immunotherapy approach to cancer treatment. Provenge is
comprised of an incompletely characterized, complex mixture of PBMCs supplemented with
a cytokine and a tumor-derived differentiation antigen, for the treatment of advanced
prostate cancer. PBMCs are obtained from the patient via leukapheresis, cultured for several
days, and then reinfused into the patient. Even though clinical results showed little evidence
of tumor shrinkage or delay in disease progression, a 4.1 month improvement in median
survival was achieved and deemed significant by the FDA. It is believed that the
professional antigen-presenting cells activated with the PA2024 fusion protein combined
with GM-CSF, which produced significant results. This is a huge accomplishment in the
field of cancer immunotherapy, and further studies are required to understand the therapeutic
mechanism of Provenge 344. Another therapy currently in late-stage phase 3 clinical trials
involves immunization with autologous DCs loaded ex vivo with a recombinant fusion
protein consisting of the tumor antigen prostatic acid phosphatase (PAP) linked to GM-CSF
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345

. Based on the success of these DC-based vaccines, it might be advantageous to try this

method with autologous DCs loaded ex vivo with HERV-K in OC patients.
An imperative issue in the development of cancer vaccines involves the appropriate
disease stage at which to administer vaccines. As dictated by medical ethics, all new phase
1 immunotherapies and many phase 2 trials must be administered to patients with advanced
disease who have failed conventional therapy. Therefore, the majority of current vaccines
focus on late-stage cancer, with little emphasis on preventative or prophylactic vaccines.
Unfortunately, patients with extensive disease are not ideal candidates in which to determine
new vaccine efficacy partly because previous therapy could have caused
immunosuppression. Therefore, the field of cancer immunotherapy must mature to a point
where vaccine can be evaluated in patients with early-stage cancers. This will allow us to
determine if HERV-K could also be effective in cancers at different stages. Another
concern in cancer vaccine development is the possibility of expression of tumor-associated
antigens in normal cells, leading to undesirable immune reactions. This deleterious sideeffect was seen experimental and clinical studies when vitiligo was induced in melanoma
patients 346, 347. Although HERV-K was not expressed in the normal tissues we studied,
future HERV-K vaccination clinical studies need to monitor this chance occurrence.
The data presented here provides the rationale for HERV-K in clinical vaccination
protocols targeting ovarian tumors expressing HERV-K, however additional assays need to
be conducted with larger sample sizes in order to ensure that HERV-K is not expressed in
normal tissues. If this data reconfirms our data, HERV-K specific vaccination strategies
have the potential to improve OC patient outcome. Performance in the clinic is the final
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arbiter of success in drug development and we believe that HERV-K vaccination should be
moved into clinical trials without hesitation. In comparison to other vaccine types we
believe that the use of a full length HERV-K protein is a superior method because it contains
a broader profile of epitopes that might be presented by DC. As innately inquisitive
scientists, our present study generated other perplexing ideas that we would like to further
investigate, as discussed below.
Stromal cells in the tumor environment stimulate epithelial cell proliferation which leads
to neoplastic transformation. This dependence of carcinoma cells on stromal support
explains the difficulty of generating a true microenvironment in vitro. The interactions
between these two cell types is extremely complex and involves exchanges of dozens of
distinct molecular species that mediate cell-to-cell signaling 243. Therefore further research
is necessary in order to correctly assimilate a comparable tumor microenvironment in vitro,
making it more representative of tumors in patients. Indeed, instead of focusing on the
intracellular signaling defects within cancer cells, new cancer therapy is directed toward
interrupting specific signaling, thereby depriving cancer cells of essential stromal support
243

.
As illustrated in Figure 13, after receiving an ascites sample from an OC patient

diagnosed with serous carcinoma, our goal was to promote stem cell growth with a serumfree and low adherent environment. After 7 days in this environment, round spherical
tumorspheres formed and the population of CD44+ stem cells increased. Most importantly,
HERV-K expression increased. This provides the exciting potential of targeting OC stem
cells via immunotherapeutic methods by exploiting their increased HERV-K expression.

122

Further studies need to be conducted on the relationship between OC stem cells and HERVK expression.
Numerous studies have indicated that HERVs may be involved in the process of
tumorigenesis. Therefore, the next step is to determine the causal relationship between
tumor development and HERV-K expression. Specifically, the regulation and effector
pathways of HERV-encoded oncoproteins need to be elucidated. Currently, a causative role
of HERVs in human tumors has not been demonstrated and future studies need to clarify this
issue. Determining the role of HERVs in the complex multi-step process leading to cancer
will shed light on the biology of cancer and also the interplay between HERVs and their
human hosts 33.
Another thought to contemplate is that the tumor or ascites specimens in our patient
cohort were obtained at primary surgery. Therefore, the immunological changes that occur
during treatment and recurrent disease are unknown and need to be explored. Also, the
positive and negative regulatory components in the tumor environment, during these periods
of treatment and recurrence need to be determined 113.
As mentioned previously, numerous preclinical studies have presented data on the
successes of vaccines in combination with other therapeutic modalities; and therefore, future
studies should determine the effect of combining HERV-K with radiation, chemotherapy,
hormone therapy, and other immunotherapies. Recent innovative techniques in
immunotherapy have been developed in order to overcome the immunogenicity of a weak
tumor-associated antigen. These include immunostimulants, adjuvant-like molecules 348, 349,
microbial products 350, 351, cytokines 352-355, and chemokines. For example, GM-CSF have
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been shown to enhance vaccine efficacy in clinical trials 331, 356-359. Preclinical studies with
the monoclonal antibody, anti-CTLA-4 combined with vaccines results in higher-avidity
antigen-specific T cells 360-362. Preclinical and early clinical studies have shown that vaccine
in combination with chemotherapeutic agents produces no detrimental effects in the immune
response 363. Future studies are needed in order to determine if these elements in
combination with our vaccine will result in enhancement of T-cell responses and antitumor
activity. Hopefully, the use of our vaccine regimen in combination with other therapies
mentioned above, will present beneficial results.
MAbs function through several different mechanisms including inhibition of tumorrelated signal transduction, induction of apoptosis, inhibition of angiogenesis, enhancing
host immune response against cancer and targeted delivery of cytotoxic agents to the tumor
site. The most important development for cancer immunotherapy are the results of the
ipilimumab phase III trials. The FDA granted broad approval in March 2011 for the use in
patients with metastatic melanoma, either as an initial therapy or after relapse. Ipilimumab is
a monoclonal antibody to CTLA4, a negative regulator of T-cell activation, and therefore
enhances host immune responses against cancer. Ipilimumab provides clear clinical
validation for cancer immunotherapy in general 344. Highlighting a different function of
mAbs, we previously reported that anti-HERV-K-specific monoclonal antibodies inhibited
growth and induced apoptosis of breast cancer cells in vitro. Also, we strengthened these
results by then showing that mice treated with 6H5 antibody showed statistically reduced
growth of xenograft tumors compared to mice treated with control mouse IgG, for tumors
originating from the established BC cells line, MDA-MB-231 96. Our results also showed
that binding of the anti-HERV-K antibody to the cell surface env signals through TP53
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pathway activation. TP53 is a tumor suppressor gene that plays a key role in apoptosis and
senescence, activation of DNA repair proteins, and cell cycle arrest at the G1/S regulation
point during DNA damage recognition. We believe that either the internalization of the
complex formed between env and the antibody or signaling through surface env after
binding of the antibody leads to TP53 pathway activation. Based on this recent success, we
would also want to establish whether anti-HERV-K protein antibodies can successfully
target ovarian tumors with the similar excellence that we accomplished in breast tumors. In
Figure 37, the effect of 6H5 on the induction of ovarian cell apoptosis was assessed by annexin
V flow cytometric assay. Cells treated with 6H5 mAb induced more early and late apoptosis
than cells treated with mouse-IgG, thus giving us confidence that anti-HERV-K antibodies could
show immunotherapeutic potential in targeting ovarian tumors. We believe that the same
mechanisms of mAb action are involved as in our BC results however more extensive research
is needed.
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Figure 37: Induction of apoptosis in established OC cells treated with anti-HERV-K 6H5
antibody. The induction of ovarian cell apoptosis was assessed by annexin V flow cytometric
assay. Cells were incubated with either 6H5 mAb (10.0 µg/ml) or mouse-IgG (10.0 µg/ml) for
16 hours at 37°C. The orange quadrant represents dead cell or cells in late apoptosis, the red
quadrant represents cells in early apoptosis and the cells in the lower left quadrant represent
viable cells. Cells treated with 6H5 mAb induced more early and late apoptosis than cells
treated with mouse-IgG.
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Moving forward, knowledge about the immune effects of anticancer mAbs can
influence our ability to use them therapeutically. This information can identify biomarkers
that can enhance our ability to select those patients who are most likely to respond to mAb
therapy. Therefore we can use immunoassays in order to personalize medicine for patients.
We can also modify the mAb structure to modulate effector mechanisms such as the ability
to bind to FcR or fix complement. The mechanism of mAb action has not been fully
elucidated, however there are several potential mechanisms that have been proposed.
Firstly, the interaction between antibody and tumor antigen may induce apoptosis by
activating mechanisms of complement-mediated cell death in the tumor cell 364. Secondly,
inhibition of ligand-receptor interaction with mAbs can lead to cell death because cells are
deprived of tumorigenic stimuli such as growth factors for proliferation, differentiation,
interaction with other cells, growth, and survival 365. Thirdly, the formation of an entire
antiidiotype network induces immunological responses against cancer cells and therefore,
the development of antiidiotype antibodies (Ab2) against Ab1-binding sites is another
important way of mAb action 366. The amount of antigen on tumor cells, the subclass of the
antibody, and the type of effector cell are some additional factors that regulate the ability of
mAbs to induce ADCC.
Multimodality approaches, based on synergistic effects observed with the
combination of antibodies with chemotherapeutic drugs and/or radiotherapy also merit
further investigation. Immune-mediated effects may be further exploited with the use of
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bispecific molecules. Stratification of patient sub-populations with tumors overexpressing
disease-related clinical biomarkers could result in improving both efficacy and specificity of
antibody-based treatment for solid tumors.
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